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ABSTRACT
Pulsatile release formulations for single dose vaccines have been studied for many
years because of the advantages that they may provide to vaccine administration with a
single dose instead of prime and booster shots.
The aim of this work is to develop novel formulations based on an In Situ Implant
(ISI) systems to provide a modified vaccine release and altered immune response, which
could act as a booster administration. This type of system was selected because ISI
systems are used for long acting administration of various drugs and ease of
administration. A typical ISI system is comprised of hydrophilic organic solvent (e.g. NMethyl-2-Pyrrolidone, NMP) and hydrophobic polymer (e.g. poly (lactide-co-glycolide),
PLGA). We have given this concept the name of AdjuGel to distinguish it from simple
drug administration. It was developed by incorporating an oil (e.g. Acetyl Tributyl
Citrate, ATBC) into an ISI system. When loaded with dissolved or suspended antigens,
AdjuGel can be injected by syringe into the body. After injection, AdjuGel will solidify
due to the dissipation of hydrophilic solvent and form an in situ semi-solid implant,
which can hold oil and antigen for a delayed release.
It was found that an AdjuGel system, composed of ethyl acetate, ATBC and a
hydrophobic polymer, such as PLGA or PLA, could stimulate delayed immune response.
The delayed period for immune response was adjustable, which was determined by the
degradation rates of polymers. A slower polymer degradation rate provided a longer
delayed period for immune response.
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CHAPTER 1.
1.1.

INTRODUCTION

History of Vaccines and Vaccine Adjuvant

1.1.1. History of vaccines
Immunization against smallpox, a process known as variolation started more than
1000 years ago in India and China. However, in 1789, Edward Jenner developed the first
scientific smallpox vaccine, which controlled this fatal disease. Jenner’s work with
cowpox vaccination is widely recognized as the foundation of modern vaccinology
because it’s the first scientific attempt to control an infectious disease with non-diseaseleading vaccination other than transmitting the disease. [2]
Vaccination is no doubt one of the most successful methods to fight diseases in
the history of human beings. Dramatic decline in the mortality and morbidity of
infectious diseases is present in Table 1-1. [6]
Vaccines can be clearly divided into three general categories: live attenuated,
killed and subunit vaccines.[1]
A live attenuated vaccine creates immunity by using weakened form of a living
microbe with reduced virulence. Since the first vaccine, smallpox vaccine, was a live
attenuated vaccine, it’s not strange that live attenuated vaccines prevailed for next one
hundred years. During this period, Louis Pasteur developed chicken cholera vaccine,
anthrax vaccine and rabies vaccines. Live attenuated vaccines contain modified live
organisms, which can cause a limited infection that induces the immune response in a
similar manner to that caused by natural infection. Compared to other vaccines, live
attenuated vaccines could induce the most potent and long-lasting immune responses
without the help of vaccine adjuvants. However, because the organism in the live
attenuated vaccines can replicate and undergo secondary mutation in the host, the
vaccines may reverse to virulence and be very dangerous under some conditions of
absence of immune competency.
A killed, or inactivated, vaccine is comprised of the killed whole organism. By
this way, the organisms cannot replicate after administration. It was developed in the end
of 19th century. In 1896 and 1897, three killed vaccines, typhoid, cholera and plague,
were invented. In the early 20th century, more killed vaccines were developed quickly,
such as pertussis vaccine, influenza vaccine and typhus vaccine. Killed vaccines cannot
replicate themselves in the host, so they cannot cause persistent infection and are safer
than live attenuated vaccine. However, because killed vaccines keep most of the
organism virulence factors and epitopes, such as LPS and Toll like Receptors ligands,
they are also very reactogenic and may induce various adverse side effects. For example,
the whole cell killed pertussis vaccine caused 13,105 cases of side effects in 1979, which
in turn lead to the development of a subunit pertussis vaccine to replace the killed whole
1

Table 1-1.

The impact of vaccines on disease burden in the US.

Disease
Smallpox
Diphtheria
Pertussis
Tetanus
Polio
Measles
Rubella
Mumps
Haemophilus
influenzae type b

Max. no. cases
(year)
48164 (1901)
206939 (1921)
265269 (1934)
1560 (1923)
21269 (1952)
894134 (1941)
57686 (1969)
152209 (1968)
20000 (1992)

Cases in 2001
0
2
4788
26
0
96
19
216
51

2

Reduction in
disease (%)
100
99.99
98.2
98.34
100
99.99
99.97
99.86
99.75

cell vaccine.[2]
Subunit vaccines contain the acellular components like toxoid, proteins or DNA.
People isolate the key components for immunization, which will protect hosts with the
least side effects. Toxoids, the inactivated bacterial toxins, are firstly used for subunit
vaccines. Diphtheria and Tetanus toxoids were widely applied as subunit vaccine for
protection from diseases of Diphtheria and Tetanus.[2] Later, many protein and
polysaccharide subunit vaccines were developed, such as vaccines for hepatitis B,
influenza and meningococcal.[2] Then DNA from the pathogen was developed for new
type of subunit vaccines as antigens. This type of vaccine contains no proteins or
polysaccharides, but use special DNA sequence encoding a protective epitope as subunit
antigens.[2] Subunit vaccines represent the development of modern vaccination with
improved safety records, specially targeting the immune responses with protective
epitopes and are cost effective to produce. However, since subunit vaccines contain the
highly purified antigens, such as recombinant proteins, they generally lack
immunogenicity and require an adjuvant and multiple doses for protection.
1.1.2. History of vaccine adjuvants
Adjuvant is a term derived from the Latin word adjuvare, which means to aid or
to help.
In 1926, Glenny and his colleagues demonstrated the adjuvant activity of
aluminum compounds with diphtheria toxoid.[2] Since then, aluminum compounds,
usually referred to as “alum adjuvants”, were widely used in the subunit vaccines. In
1937, Freund and his colleagues found the famous and powerful Freund’s complete
adjuvant (FCA), which is composed of a water in mineral oil emulsion (W/O) containing
killed mycobacteria.[3] Later, it was found that killed mycobacteria are not needed in
some cases and the Incomplete Freund Adjuvant was developed,[4] which is composed
of a water in mineral oil emulsion without killed mycobacteria.
Generally, vaccine adjuvants are indispensable in most of the subunits vaccines.
There are several important functions of vaccine adjuvants in vaccines. Firstly, vaccine
adjuvant can enhance the immune response and also affect the onset and duration of
immune response. Some vaccine adjuvants may induce fast and strong responses, while
some adjuvants may generate delayed responses or extend the longevity of responses.
Secondly, vaccine adjuvants can modify the immunophenotype or the quality of immune
response that vaccines generate in the host. Different vaccines need different types of
immune reaction (e.g. Th1 or Th2 type of immune response) to protect against diseases.
By this function, vaccine adjuvants can determine the efficacy of the vaccines. Thirdly,
vaccine adjuvants dramatically reduce the amount of antigen required to induce a
protective immune response. Without adjuvants, it was found that more than ten times of
antigen amount would be need to induce similar or less immune response compared to
the vaccine with adjuvant. [5] Finally, vaccine adjuvants can also improve the antigens
stability and extend the vaccines’ shelf life. In most of the case, vaccine adjuvants may
3

stabilize the vaccine antigens both in vitro and in vivo by sheltering the fragile antigens
from contact with unfavorable surrounding.
Currently, many types of vaccine adjuvants have been developed to boost immune
response. By mechanisms of action, Vaccine adjuvants are usually divided into two
classes: delivery systems and immunopotentiators.[6] Some examples are showed in
Table 1-2.[6]
1.1.2.1.

Alum adjuvant

Alum is an abbreviation of aluminum salts, which include salts of aluminum
hydroxide and aluminum phosphate. Alum was first used as a vaccine adjuvant in 1926
and since then, became the most widely used adjuvant. Although Alum adjuvant is a
relatively weak adjuvant, it has a long safety record. For more than fifty years, alum
adjuvant has been the only adjuvant in a vaccine approved for use in humans. This finally
changed before the turn of the century when Novartis's (Chiron) MF59®, an oil based
adjuvant, received approval for use in Europe in 1997. Twelve years later, the US FDA
approved a new adjuvant ASO4 (A combined adjuvant' system containing Aluminium
Hydroxide and another immune modulator called monophosphoryl lipid A) , which was
used in GlaxoSmithKline Biologicals's Cervarix, for prevention of cervical cancer and
precancerous lesions caused by human papillomavirus (HPV) types 16 and 18.[7]
Vaccines with Alum adjuvant are prepared by allowing the antigen to be absorbed to
Alum. The forces responsible for the adsorption of antigen include hydrophobic
interactions, van der waals forces, ionic charges and hydrogen bonding. [1]The
mechanism of the adjuvanticity of Alum is not completely clear. There are three potential
mechanisms to explain why Alum can induce immune response:[2]
1.
2.

3.

The depot mechanism. The antigen is adsorbed on Alum adjuvant and is released
slowly to stimulate the production of antibodies.
The inflammation mechanism. It is based on the hypothesis that Alum adjuvant
can cause inflammation at the site of injection, which attracts antigen presenting
cells (APCs), such as dendritic cells and macrophages, to process the attached
antigen in the injection site.
Adsorption of antigen to Alum adjuvant converts the soluble antigen to a
particulate form, which will facilitate APCs to take up antigen by phagocytosis.
It’s believed that the three mechanisms work together to provide the adjuvanticity
of Alum adjuvant and further studies are still needed for elucidating the
mechanisms.

1.1.2.2.

Oil based adjuvants

In the various formulations of vaccine adjuvants, oil based vaccine adjuvants are
among the most widely used adjuvants. Since Dr. Freund developed the famous Freund
Adjuvant, many studies were conducted on the mechanisms and formulations of oil based
vaccine adjuvants. Freund adjuvant was very effective, but poorly tolerated due to the use
of non-degradable mineral oils, so better tolerated oils were extensively explored. In
4

Table 1-2.

Two classes of vaccine adjuvants.

Antigen delivery systems
Insoluble aluminum compounds
Calcium phosphate
Liposomes
Virosomes™
ISCOMS® (Immune stimulating
complexes)
Microparticles (e.g., poly (lactide-coglycolide), PLGA)
Oil-based Emulsions (e.g., IFA, MF59,
Montanides)
Virus-like particles & viral vectors

Immunopotentiators
MPL (Monophosphoryl lipid A) and
synthetic derivates
MDP (Muramyl dipeptide) and derivatives
Oligonucleotides (CpG, etc.)
Double-stranded RNA (dsRNA)
Alternative pathogen-associated molecular
patterns (PAMPs) (E. coli heat labile
enterotoxin (LT); flagellin)
Saponins (Quils, QS-21)
Small-molecule immune potentiators (
SMIPs) (e.g., resiquimod [R848])
Cytokines & chemokines

5

1960s, different biodegradable vegetable oils were tested in oil based adjuavnts. In 1997,
MF59 was approved for use in humans. MF59 is an oil-in-water microemulsion that
includes squalene (derived from biodegradable plant oil), Polysorbate 80, and Span
85(two surfactants).
The formulation of oils based vaccine adjuvant could be water in oil emulsion
(e.g. IFA), oil in water emulsion (e.g. MF59) or a more complicated emulsion systems
(e.g. oil in water in oil emulsion,). However, all oil based vaccine adjuvants need two
necessary components in the formulation: oil and surfactant.[5] Recently, Calabro and his
colleagues conducted series of experiments and demonstrated that “The adjuvant effect of
MF59 is due to the oil-in-water emulsion formulation, none of the individual components
induce a comparable adjuvant effect”. [8] Now it is clear that only the combination of oil
and surfactant can induce the adjuvant effects or immune response, any individual
component, oil or surfactant alone, was not able to induce comparable immune response.
1.1.2.3.

Polymer vaccine adjuvants

Polymer vaccine adjuvants have been studied for long time as vaccine delivery
systems. Because polymer adjuvants have the ability of sustained release of vaccine
antigens, the main purpose of polymer adjuvants is to develop single dose vaccines. In
1970s, people started to use non-biodegradable polymer implants to develop new vaccine
delivery systems. [9] Later, biodegradable polymers were introduced because
biodegradable polymers didn’t need to be removed by surgical procedure after
administration. Since 1990s, microparticles composed of biodegradable polymers have
become the most widely studied formulation as vaccine delivery systems due to the ease
of administration.[10, 11]
Two types of biodegradable polymers, polyesters and polyanhydrides, are most
widely studied as vaccine delivery systems.
The most important polyester is poly (lactide –co-glycolide) or PLGA. PLGA was
initially utilized in biomedical applications such as biodegradable surgical sutures and
pins. In 1990s, PLGA microparticles were proven effective to induce protective immune
responses as a vaccine delivery system. [12, 13] However, when PLGA degrades in vivo,
lactic acid and glycolic acid are release and acidic microenvironment is created, which
has been showed to be detrimental to the stability of antigen proteins. [14] In order to
overcome the problem, some attempts were applied to decrease the acidity. For example,
magnesium carbonate, a basic compound, was added into PLGA microspheres for
stabilizing the synthetic human chorionic gonadotropin (hCG) peptide antigen.[15]
Currently, two mechanisms are available for the PLGA microparticles function as
vaccine delivery system: [16] one is the PLGA microparticles form a depot for the
antigen; another is PLGA microparticles enhance the APCs uptake of antigen loaded
particles due to their small size. Although particle size is a key issue in the development
of effective PLGA microparticles as a vaccine delivery system, the exact relationship
between particle size and host immune responses is not clear. [17] There are different
6

views on the relationship of particle size and the immune responses. Some believed
smaller particle size intends to induce stronger immune responses, but other observations
also found larger particle size might promote stronger immune responses or there was an
optimum particle size that could stimulate the strongest immune response. [17]
Extensive research was done with the PLGA microparticles as antigen carriers.
However, the studies still couldn’t demonstrate clear correlation between release pattern
of antigenic peptides, length of in vitro release of antigens, and host immune responses.
[1] Because of the variation in dose of antigen, method of formulation (e.g. solvent
evaporation vs. spray drying), route of administration, and the size of the microparticles,
the efficacy of PLGA microparticles was not consistant in many experiments,[18] and
there is no clinical trial undergoing currently with the PLGA microparticles as a vaccine
delivery system. Obviously, more efforts are needed for the mechanisms and
formulations of PLGA microparticles before the technique may be applied in humans.
Polyanhydrides are a class of surface erodible, biodegradable and biocompatible
polymers that were widely used in controlled drug delivery systems.[19] After
administration, polyanhydrides degrade into non-toxic di-acid monomers that can be
metabolized and eliminated from the body. The surface erosion mechanism of
polyanhydrides leads to a more predictable controlled release profile, which may range
from days to months.
The most important advantage of polyanhydrides over polyesters as a vaccine
delivery system is their ability to stabilize the antigen proteins. Many studies have proven
that polyanhydrides are able to stably maintain polypeptides and show sustained release
of polypeptides.[20, 21] The surface erosion characteristics of polyanhydrides can
prevent water from penetrating into the interior of the microsphere and keep the
encapsulated antigen in the native state. Moreover, the degradation products of
polyanhydrides, di-acid monomers, are usually less acidic than those of PLGA polymer,
which could provide a moderate pH microenvironment leading to stability of the
encapsulated antigen and maintenance of antigenic epitopes and also reduce surrounding
tissue reactions to the polymer.[22]
Despite the advantages of polyanhydrides in stabilizing the entrapped antigens, a
major obstacle for the use of polyanhydride based microparticles , however, is their
limited uptake by dendritic cells (DCs). In order to solve this problem, recently, Phanse et
al.[23] functionalized the polyanhydride microparticle surface with di-mannose in order
to target C-type lectin receptors (CLRs) on DCs. Polyanhydride particles based on
sebacic acid (SA), 1,6-bis(p-carboxyphenoxy)hexane (CPH) and 1,8-bis(pcarboxyphenoxy)-3,6-dioxaoctane (CPTEG) were evaluated. Di-mannose-functionalized
polyanhydide microparticles were found to up-regulate the expression of CLRs on DCs,
and more importantly, di-mannose functionalization also increased the DCs uptake of
polyanhydride microparticles, which may enhance delivery of encapsulated antigens and
potentially induce a more robust adaptive immune response.
Many naturally derived polymers such as chitosan, dextran, starch and alginate
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have also been explored as vaccine delivery system. [24-27] In addition, some novel
synthetic polymers such as poly (ester-amide) (PEA) copolymer and poly (propylene
sulfide) were studied for development of new vaccine delivery system.[1]
1.1.3. What’s the ideal vaccine adjuvant?
In 2009, O’Hagan et al. [28] described what are the characteristics of successful
and unsuccessful adjuvants.(see Table 1-3)
Vaccines should be safe and, at the same time, able to induce potent and longlasting immune responses. Because subunit vaccines usually require at least 3-5 doses to
achieve protective immunity, compliance became a significant issue in vaccination
programs. It’s noted that dropout rates could reach 70% in some developing countries,
which resulted in millions deaths annually from vaccine preventable diseases such as
tetanus and pertussis.[29] In 2005, WHO listed the development of single dose vaccine
as the No.1 of “Grand Challenges” in global human health. [30] [30] [30] [25] Not only
in human vaccination, but in livestock systems, it’s also very hard and expensive to
handle the[30][30][30] large numbers of animals for multiple inoculations.[31]
In order to meet the requirement of single dose vaccines, numerous new adjuvants
have been studied to approach the goal.
1.2.

Current Status for Development of Adjuvants for Single Dose Vaccine

For subunit vaccines, there are generally two strategies to develop single dose
vaccines: use a potent adjuvant (e. g. Freund complete adjuvant) or simulate multiple
injections by controlled release of vaccines. Because potent adjuvants probably bring
increased safety concerns, they are rarely used to design single dose vaccines. Therefore,
controlled release of vaccines is mostly applied to design of single dose vaccines.
In 1979, Preis and Langer used non-biodegradable polymer implants for delivery
of low dose protein antigen to mice, which showed strong and prolonged immune
responses induced by sustained release of antigen.[9]
In 1991, O’ Hagan et al. used biodegradable polymer (PLGA) microparticles for
delivery of entrapped protein antigen to mice, which induced strong immune responses
comparable to antigen dispersed in Freund’s complete adjuvant.[10] PLGA is a polyester
composed of lactic and/or glycolic acid monomers. PLGA has a long safety record and
can be easily processed into almost any shape and size. The advantages for using PLGA
microparticles as an adjuvant are: 1. controlled release of antigens for extended time
periods; 2. ability to induce cytotoxic T-cell (CTL) responses,[32] which are important
but absent for classic adjuvants.
Because of the advantages of PLGA microparticles for antigen delivery, PLGA
8

Table 1-3.

Characteristics of unsuccessful and successful adjuvants.

Unsuccessful adjuvants
Unacceptable tolerability profile
Significant local reactions
Complex, difficult to scale up, lack of
reproducibility in formulation
Raw materials expensive or not available of
suitable purity from reliable source
Non degradable, leaves long term residue at
injection sites
Difficult to formulate with diverse antigens,
negative impact on antigen stability
Inflexible, not easy to combine with additional
formulation components

Successful adjuvants
Safe, not associated with any long term effects
Well tolerated
Simple synthetic pathway
Simple inexpensive components
Biodegradable
Compatible with many different kinds of
vaccine antigens
Capable of co-delivery of antigen and immune
potentiator
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microparticles attracted extraordinary attention as a new type of vaccine adjuvant or
delivery system. [33] [34] [35] However, although PLGA microparticles held many
strongly desirable properties for single dose vaccines, after more than 20 years
development, there are still no human clinical studies conducted with these novel vaccine
delivery systems. Several significant hurdles impeded the progress of studies of PLGA
microparticles as vaccines delivery systems. Such as: antigen instability when
incorporated into the microparticles; high cost of manufacture process and difficulties in
following the Good Manufacturing Practice (GMP) during the scale up.[16]
Although it is well known that controlled release of antigens are critical for
development of new delivery systems for single dose vaccines, no clear correlation was
established between release of antigens and immune response in vivo, which has become
a difficukt hurdle for the further research on the new vaccine delivery system.
1.3.

What Is the ISI (In Situ Implant) System and Why Was It Chosen for
Modifying Antigen Release?

ISI systems have been developed as an alternative to solid implant and
microparticle formulations.[36, 37] An ISI system is an biodegradable hydrophobic
polymer (usually PLGA) solution, which is formed by dissolving biodegradable polymer
into biocompatible solvents (e.g. NMP).[37] When loaded with bioactive agents by
dissolved or suspended, the ISI system can be injected by syringe into the body. As
biodegradable hydrophobic polymer is water insoluble, contacting with the physiologic
aqueous surroundings leads to the dissipation of biocompatible solvent, causing the
polymer solution to undergo phase separation to form an in situ solid or semi-solid
implant.[37] The structure of solidified implant may exhibit a core with large pores of
diameters from about 10 to 500 microns and a relatively nonporous skin as a membrane
barrier, which has extremely fine pores of 0.01 to 0.1 microns in diameter.[38]
The solidifying process of ISI system is schematically demonstrated in the Figure
1-1. First, the homogeneous solution of PLGA polymer and solvent with drug sits on the
supporter with non-solvent quenching bath surroundings, which belongs to the aqueous
phase. Then solvent non-solvent exchange happens, which lead to phase inversion and
PLGA precipitation. Finally, the PLGA polymer solution transforms into an implant
device with a porous core and a relatively nonporous skin.[39]
Extensive studies were conducted for the ISI system as the controlled release
delivery system. Krebs and his colleagues used Micro-CT to study the cross section of
ISI system with PLGA polymer. [40] It is clearly showed a porous core and dense skin
(Figure 1-2).
Based on the in vitro study above, Krebs, et al also studied the transformation of
ISI system in vivo.[40] Figure 1-3 shows the structure of solidified ISI system formed in
vivo. It also formed a porous inside and dense skin similar to Figure 1-2.
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Figure 1-1. Schematic of phase inversion process.
Schematic of phase inversion process showing transformation of solution consisting of
polymer (P) and solvent (S), with dissolved or suspended drug (D), to a two-phase
membrane structure. (Reprinted with permission: McHugh, A.J., The role of polymer
membrane formation in sustained release drug delivery systems. J Control Release, 2005.
109(1-3): p. 211-21.)
P: Polymer (e.g. PLGA); S: Solvent (e.g. N-Methyl-2-pyrrolidone, NMP); NS: Nonsolvent (e.g. water); D: Drug (e.g. Ovalbumin)
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Figure 1-2. Micro-CT images of a cross-section through a solidified ISI system
made from 50:50 PLGA (Quenched by PBS buffer).
Scale bars represent 1 mm. (Reprinted with permission: Krebs, M.D., et al., Injectable
poly(lactic-co-glycolic) acid scaffolds with in situ pore formation for tissue engineering. Acta
Biomater, 2009. 5(8): p. 2847-59.)
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Figure 1-3. SEM photomicrographs of solidified ISI system formed in vivo (After
24-hours S.C. injection in mice).
A is from the interior of the implant, B is from the exterior of the implant. All scale bars
represent 200 um. (Reprinted with permission: Krebs, M.D., et al., Injectable poly(lacticco-glycolic) acid scaffolds with in situ pore formation for tissue engineering. Acta Biomater,
2009. 5(8): p. 2847-59.)

13

ISI systems were applied in the FDA approved drugs as sustained release delivery
systems. Many studies were also performed to evaluate the potential of ISI system for
delivery of proteins and peptides. When incorporated with lyophilized proteins, ISI
system showed various sustained release profiles with the changes of different parameters
(e.g. polymer types, polymer concentrations and biocompatible solvents, Figure 1-4)[41].
Although ISI system showed the potential for the control release of proteins and
peptides, little data was published on the ISI system as the vaccine delivery system. in
1999, Terry Bowersock and Stephen Martin did some experiments to evaluate the
possibility to use ISI system as adjuvant to develop the single dose vaccines or selfboostering vaccines.[31] They tested many formulations in pigs and finally concluded
that “The profile of the immune response was similar to that seen with classical
adjuvants”.[31] It seemed ISI system did not exhibit special adjuvanticity even though it
held the ability of prolonged release for protein antigens.
It differed from the microparticle systems, which could enhance the immune
responses to antigen due to their small size, [33, 42, 43] and the ISI system did not
exhibit strong adjuvanticity and self-boostering in Bowersock’s experiment. People
usually believe the ISI system, based on biodegradable polymer PLGA, is an inert
system, which is not suitable as vaccine delivery system. However, because the ISI
system renders strong potential for the sustained release of proteins and peptide, we
decided to develop ISI system as a new delivery system for single dose vaccines.
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Figure 1-4. Release of FITC-BSA from PLGA systems.
(a) Release of FITC-BSA from high molecular weight PLGA systems in PBS. (b)
Release of FITC-BSA from low molecular weight PLGA systems in PBS. (Reprinted
with permission: Packhaeuser, C.B., et al., In situ forming parenteral drug delivery systems:
an overview. Eur J Pharm Biopharm, 2004. 58(2): p. 445-55.)
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CHAPTER 2. DEVELOPMENT OF NEW VACCINE FORMULATIONS WITH
STRONG ADJUVANTICITY BASED ON ISI SYSTEM
2.1.

Formulation Screening

2.1.1. Introduction
Initial experiments in 2009 were initiated with the single dose Porcine Zona
Pellicida (PZP) vaccine project in cooperation with Science and Conservation Center,
Zoo Montana. PZP is a non-cellular membrane surrounding all mammalian eggs, which
consists of three glycoproteins called ZP1, ZP2 and ZP3. PZP vaccine is a promising
contraceptive vaccine under research for more than 30 years, which has been used to
contracept deer, horse, elephant, wolf, sheep and many other species.[44, 45] Because
PZP vaccine is mainly used for contraception of free roaming animals, multiple injections
are impractical for field applications. In order to overcome the drawbacks of multiple
inoculations, we designed new type of delivery system based on In Situ Implant (ISI)
system to approach the goal of single inoculation.
Oil-based vaccine adjuvants, such as CFA, IFA and MF59, are probably the most
effective adjuvants to stimulate immune responses. In order to enhance the adjuvanticity
of vaccine delivery systems, different hydrophobic oils have already been incorporated
into the microcapsule systems. [46] [47]. Because previous data [31] showed an ISI
system alone could not induce strong immune response, a hydrophobic oil was
considered for incorporation into an ISI system.
Mineral oil, squalene and vegetable oils were first considered as the additional
components. However, mineral oil, squalene and vegetable oils were not miscible with
ISI system (PLGA and organic solvent NMP solution) and they formed oil in oil
emulsion after mixture. The oil in oil emulsion is not stable at room temperature and the
separation happened quickly. In order to obtain a stable formulation, a hydrophobic
plasticizer Acetyl Tributyl Citrate (ATBC) was introduced into ISI system. Plasticizer
ATBC can be easily dissolved in the ISI system which composed of NMP and PLGA.
The system with NMP, ATBC and PLGA formed a clear and stable solution formulation
at room temperature.
Since Eligard®, the first FDA approved drug with ISI system, is formulated with
PLGA and N-Methyl-2-pyrrolidone (NMP), we used NMP as the organic solvent in the
first animal experiment. Since female rabbits are the model animals for study of PZP
vaccine. New Zealand female rabbits were chose in the experiment.
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2.1.2. Experimental procedures
2.1.2.1.

Materials

Twenty four white New Zealand female rabbits were ordered from Myrtles
Rabbitry. The biodegradable polymer PLGA was ordered from Lactel Absorbable
Polymers, Durect Corporation, Pelham, AL, USA. NMP was obtained from ISP Pharm
Technologies; Acetyl Tributyl Citrate (ATBC) was obtained from Morflex Inc,
Greensboro, NC, USA; Lyophilized PZP as the antigen was obtained from Science and
Conservation Center, Zoo Montana and modified Freund adjuvant (MFA) was ordered
from Sigma.
PLGA (poly (lactide-co-glycolide)) is a copolymer which is used in a lot of FDA
approved therapeutic devices, owing to its biodegradability and biocompatibility. PLGA
is synthesized with two different monomers, the cyclic dimers (1,4-dioxane-2,5-diones)
of glycolide and lactide. Chemical structure is shown below in Figure 2-1.
NMP (N-Methyl-2-pyrrolidone) is a clear to slightly yellow liquid miscible with
water and other organic solvents, which belongs to the class of dipolar aprotic solvents.
Chemical structure is shown below in Figure 2-2.
Acetyl Tributyl Citrate (ATBC) is an innocuous and biodegradable plasticizer or
carrier solvent permitted in the field of food additives, food contact material as well as for
polymers. It was chosen as the oil because it could be easily dissolved into the NMP,
PLGA solution and formed a clear formulation. Chemical structure is showed below in
Figure 2-3.
2.1.2.2.

Formulation process
Formulation process of the PZP vaccine (all steps were prepared aseptically):

1.
2.

3.

Prepare a blank gel consisting of a blend of PLGA and a combination of NMP
AND !4"# AT #-#
An appropriate quantity of gel was weighed and transferred in to an autoclaved
clean glass vial. An appropriate quantity of PZP was weighed and blended with
the gel and resulting mixture was stirred to obtain uniform mixture of PZP-loaded
gel.
Each dose of PZP-loaded gel contains 100ug of PZP per 0.5ml gel. The final
formulation is a suspension of PZP in the clear gel solution.

2.1.2.3.

Immunization of animals

For all the immunization experiments, Lyophilized PZP protein was dissolved in
PBS buffer or was suspended in organic solvent NMP or different gel formulations
immediately before injection to obtain a concentration of 200ug/ml. All rabbits were
given single IM inoculation at day 0. Experimental assignment was shown in Table 2-1.
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Figure 2-1.

PLGA chemical structure.
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Figure 2-2.

NMP chemical structure.
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Figure 2-3.

ATBC chemical structure.
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Table 2-1.

Rabbit experimental group assignment in PZP study.

Group Treatment

Number of
rabbits
3

1

Control

2

NMP control

3

3

Modified CFA+PZP

3

4

Gel 1 + PZP

3

5

Gel 2 + PZP

3

6

Gel 3 + PZP

3

7

Gel 2+ ATBC+ PZP

3

8

Gel 2+ Modified CFA+
PZP

3

Description
IM injection with PBS buffer and
PZP (100ug for all PZP)
IM injection with NMP and
PZP
IM injection with Modified CFA and
PZP
IM injection with NMP plus low
molecular weight PLGA gel and PZP
IM injection with NMP plus medium
molecular weight PLGA gel and PZP
IM injection with NMP plus medium
molecular weight PLGA gel and PZP
IM injection with NMP plus low
molecular weight PLGA gel and PZP
IM injection with NMP plus
PLGA gel and Modified CFA plus
PZP

The final volume of each group is 0.5ml.
The PLGA polymer in Group 5, 7 and 8 is medium molecular weight PLGA (50:50) (IV:
0.55 - 0.75; product No. B6010-2, Durect Corporation).
The PLGA polymer in Group 4 is the low molecular weight PLGA 50:50 (IV: 0.15 0.25; Product No. B6017-1, Durect Corporation)
The PLGA polymer in Group 6 is high molecular weight PLGA 85:15 (IV: 0.55 - 0.75;
Product No. B6006-1, Durect Corporation)
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2.1.2.4.

Procedures

All groups were inoculated IM once at day 0 and blood samples were collected
every 2 weeks in the first 2 months and every 3 or 4 weeks thereafter. Blood samples
were serially diluted with 0.05% Tween 20 in PBS: 1:1,000, 1:10,000, 1:100,000 and
1:1,000,000. IgG titers were checked by ELISA (Enzyme-Linked Immunosorbant
Assay); use Log10EC50 as a measure of immune response. EC50 means half maximal
effective concentration and the absorbance of 1:1000 dilution was used as the maximum.
2.1.2.5.

Enzyme linked immunosorbent assay (ELISA)

96-well microtiter plates (high protein binding plates from Costar) were coated
overnight with 100 μl coating solution containing 3 μg/mL PZP protein at 4 ϶C. To
remove unbound PZP, plates were washed three times with PBS (pH 7.4) containing
0.05% Tween 20 (PBST). Serum samples (100 μL/well) from individual mice were
serially diluted in PBST: 1:1,000, 1:10,000, 1:100,000 and 1:1,000,000. The plates were
then incubated for two hours at room temperature. The plates were again washed three
times with PBST followed by addition of 100 μL of PBST containing Horseradish
Peroxidase (HRP) -conjugated goat anti-rabbit IgG (diluted 1:4000) (Abcam, ab6721).
After a two hour incubation period at room temperature, the plates were washed three
times with PBST followed by the addition of 200 μL of 0.4 mg/ml OPD Peroxidase
Substrate (Sigma P9187, Sigma-Aldrich, St. Louis, MO) and allowed to react for 30
minutes at room temperature. The optical density (OD) of the reaction was measured at
450 nm using a Plate Reader. Software BioDataFit was applied to deal with the data by
the four-parameter model. Serum titers are reported with Log10EC50.
2.1.2.6.

Statistical analysis

Results are expressed as mean ± S.D. Statistical analysis was carried out for
analyses of differences between means of serum antibody titers using Student’s twotailed t-test. Differences in means were accepted as significant if P was less than 0.05.
2.1.3. Results and discussion
Serum titers were reported with Log10EC50 and results was showed in Table 2-2
and Figure 2-4. Table 2-2 showed the means of serum anti-PZP IgG antibody titers and
standard deviations.
In this experiment, the formulations with only organic solvent NMP and three
different types of PLGA (Group 4, 5 and 6) didn’t induce strong immune response. At
week 6, there are no significant differences among the negative control (group 1), group
4, 5 and 6 (P > 0.05). However, when incorporated with ATBC and modified Freund
adjuvant (mineral oil) in group 7 and 8, they both exhibited much stronger immune
response. At week 6, there are significant differences between ATBC group (group 7)
and non-ATBC group (group 4) (P < 0.05). Since the formulation of group 8 formed an
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Table 2-2.
The results of serum anti-PZP IgG antibody titers for group 1, 2, 3, 4, 5, 6, 7 and 8 at different time
points of day 0, week 2, 4, 6, 8, 11, 15, 18, 22, 24, 26, and 28.
Time
G1
G2
G3
G4
G5
G6
G7
day 0
0±0
0±0
0±0
0±0
0±0
0±0
0±0
2 weeks
0.4±0.16
0.48±0.07
1±0.5
0.59±0.2
0.59±0.1
0.29±0.06
0.9±0.28
4 weeks
0.44±0.14
0.34±0.1
1.58±0.33
0.62±0.07
0.86±0.04
0.36±0.17
1.19±0.23
6 weeks
0.63±0.05
0.31±0.1
2.34±0.15
0.78±0.09
0.81±0.18
0.52±0.27
1.31±0.19
8 weeks
0.58±0.14
0.2±0.09
2.39±0.48
0.7±0.1
0.53±0.12
0.42±0.41
1.18±0.43
11 weeks
0.32±0.11
0.19±0.16
2.36±0.53
0.32±0.13
0.54±0.21
0.22±0.21
0.71±0.23
15 weeks
0.28±0.12
0.1±0
2.13±0.43
0.1±0
0.13±0.05
0.22±0.18
0.87±0.32
18 weeks
0.16±0.11
0.1±0
2.05±0.45
0.12±0.03
0.19±0.1
0.15±0.08
0.48±0.13
22 weeks
0.16±0.05
0.1±0
2.14±0.58
0.1±0
0.16±0.1
0.13±0.06
0.51±0.33
24 weeks
0.13±0.06
0.1±0
2.03±0.57
0.1±0
0.15±0.09
0.12±0.03
0.36±0.14
26 weeks
0.1±0.06
0.1±0
1.95±0.76
0.1±0
0.1±0
0.1±0
0.39±0.24
28 weeks
0.1±0.06
0.1±0
1.71±0.55
0.1±0
0.1±0
0.1±0.03
0.26±0.1
P value
(6 weeks)
0.075*
0.202**
0.549***
0.030****
Serum anti-PZP IgG antibody titers were reported with Log10EC50 and results were presented as Mean ± S.D.
P values with 6 weeks results (*G4 vs. G1; **G5 vs. G1; ***G6 vs. G1; ****G5 vs. G7)
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G8
0±0
0.69±0.23
1±0.17
1.35±0.18
1.49±0.41
1.44±0.36
1.49±0.41
1.15±0.4
1.41±0.39
1.21±0.5
0.94±0.49
0.98±0.52

Figure 2-4.

Rabbit serum anti-PZP IgG titers with multiple time points.
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oil in oil emulsion and the emulsion was not stable, we didn’t conduct further studies for
this formulation. The formulation with organic solvent NMP, PLGA and ATBC was a
stable and clear solution, which we chose as the candidate for further development.
2.1.4. Conclusions
From the results we got, we concluded that: 1. The gel comprised of NMP and
PLGA (ISI system) didn’t show good adjuvanticity, which is compatible with previously
published data. 2. The gel comprised of NMP, PLGA and ATBC (called AdjuGel
system) can induce strong immune responses and it is a new type of vaccine adjuvant or
delivery system which has potent ability for the sustained release of both antigens and
vaccine adjuvants. 3. The gel comprised of NMP, PLGA and ATBC (called AdjuGel
system) demonstrated potential as a long acting system for administration of PZP for
contraception.
2.2.

Study the AdjuGel System and Determine If PLGA Is Necessary for
Adjuvanticity

2.2.1. Introduction
Because AdjuGel system is a new type of vaccine adjuvant, we need to study this
new formulation to clarify what’s the key component for its adjuvanticity. In previous
experiment, we obtained the result that organic solvent NMP alone (group 2) cannot
induce an effective immune response. However, NMP is well known as a chemical
penetration enhancer, [48] and is widely used for enhancement of transdermal delivery of
different hydrophilic and hydrophobic drugs.[49] NMP can also induce the local
inflammation after IM injection. [50] We assumed NMP may play a role in the
adjuvanticity of AdjuGel system. PLGA polymers have been widely utilized in
biomedical applications such as therapeutic devices and biodegradable surgical sutures
due to their biodegradability and biocompatibility. It is well accepted that PLGA
polymers are inert and cause little local inflammation. Based on the characteristics of
NMP and PLGA polymers, we set up a new animal experiment to answer several
questions: 1. is biodegradable polymer PLGA indispensable for the adjuvanticity? 2. may
ATBC alone good enough for adjuvanticity? 3. is NMP plus ATBC a good formulation
of vaccine adjuvant?
2.2.2. Experimental procedures
2.2.2.1.

Materials

24 white New Zealand female rabbits were ordered from Myrtles Rabbitry. The
biodegradable polymer PLGA was ordered from Lactel Absorbable Polymers, Durect
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Corporation, Pelham, AL, USA. NMP was obtained from ISP Pharm Technologies;
Acetyl Tributyl Citrate (ATBC) was obtained from Morflex Inc, Greensboro, NC, USA;
Lyophilized Ovalbumin (OVA) as the antigen was purchased from Sigma; Alum was
ordered from Thermo Scientific.
2.2.2.2.

Formulation process

Formulation process of the OVA vaccine (all steps were prepared aseptically): 1.
Prepare a blank gel consisting of a blend of PLGA and a combination of NMP and ATBC
AT #-# 2. An appropriate quantity of gel was weighed and transferred in to an
autoclaved clean glass vial. An appropriate quantity of OVA was weighed and blended
with the gel and resulting mixture was stirred to obtain uniform mixture of OVA-loaded
gel. 3. Each dose of OVA-loaded gel contains 100ug of OVA per 0.5ml gel. The final
formulation is a suspension of OVA in the clear gel solution.
2.2.2.3.

Immunization of animals

For all the immunization experiments, Lyophilized OVA protein was dissolved in
PBS buffer or was suspended in organic solvent NMP, plasticizer ATBC or AdjuGel
system immediately before injection to obtain a concentration of 200ug/ml. Experimental
assignment was shown in Table 2-3.
2.2.2.4.

Procedures

All groups were inoculated IM once at day 0 and blood samples were collected
every 2 weeks. Blood samples were serially diluted with 0.05% Tween 20 in PBS:
1:1,000, 1:10,000, 1:100,000 and 1:1,000,000. IgG titers were checked by ELISA
(Enzyme-Linked Immunosorbant Assay); use Log10EC50 as a measure of immune
response. EC50 means half maximal effective concentration and the absorbance of
1:1000 dilution was used as the maximum.
2.2.2.5.

Enzyme linked immunosorbent assay (ELISA)

96-well microtiter plates (high protein binding plates from Costar) were coated
overnight with 100 μl coating solution containing 3 μg/mL ovalbumin (OVA) at 4 ϶C. To
remove unbound OVA, plates were washed three times with PBS (pH 7.4) containing
0.05% Tween 20 (PBST). Serum samples (100 μL/well) from individual mice were
serially diluted in PBST: 1:1,000, 1:10,000, 1:100,000 and 1:1,000,000. The plates were
then incubated for two hours at room temperature. The plates were again washed three
times with PBST followed by addition of 100 μL of PBST containing Horseradish
Peroxidase (HRP) -conjugated goat anti-rabbit IgG (diluted 1:4000) (Abcam, ab6721).
After a two hour incubation period at room temperature, the plates were washed three
times with PBST followed by the addition of 200 μL of 0.4 mg/ml OPD Peroxidase
Substrate (Sigma P9187, Sigma-Aldrich, St. Louis, MO) and allowed to react for 30
minutes at room temperature. The optical density (OD) of the reaction was measured at
450 nm using a Plate Reader. Software BioDataFit was applied to deal with the data by
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Table 2-3.

Rabbit experimental group assignment in OVA study.

Group Treatment
1
2
3
4
5
6
7
8

Control
NMP control
ALUM+OVA
ATBC + OVA
ATBC+NMP+OVA
ATBC+NMP+OVA
ATBC+NMP+OVA
AdjuGel + OVA

Number
of
rabbits
3
3
3
3
3
3
3
3

Description

IM injection with PBS buffer and OVA
IM injection with NMP and OVA
IM injection with ALUM and OVA
IM injection with ATBC and OVA
IM injection with ATBC and NMP (2:1 V/V) plus OVA
IM injection with ATBC and NMP (1:1 V/V) plus OVA
IM injection with ATBC and NMP (1:2 V/V) plus OVA
IM injection with ATBC and NMP (1:1 V/V) plus PLGA and
OVA
Ovalbumin is 100ug per injection. The volume is 0.5ml per injection.
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the four-parameter model. Serum titers are reported with Log10EC50.
2.2.2.6.

Statistical analysis

Results are expressed as mean ± S.D. Statistical analysis was carried out for
analyses of differences between means of serum antibody titers using Student’s twotailed t-test. Differences in means were accepted as significant if P was less than 0.05.
2.2.3. Results and discussion
Serum titers were reported in Table 2-4 and Figure 2-5.
Biodegradable hydrophobic polymers PLGA are thought to be inert materials, so
we assumed the removal of PLGA would not affect the adjuvanticity of AdjuGel.
However, none of the groups (group 4, 5, 6 and 7) without PLGA exhibited adjuvanticity.
AT time points of week 4, 6 and 8, the group 8, composed of NMP, PLGA and ATBC,
induced a much stronger immune response than the Alum group (P < 0.05). Clearly,
polymer PLGA played a key role in the AdjuGel as a vaccine adjuvant.
2.2.4. Conclusions
From the study and results above, we concluded that: 1. In the AdjuGel formula
of NMP, PLGA and ATBC, the PLGA polymer as well as ATBC is indispensable for the
adjuvanticity. 2. The AdjuGel system induced a much stronger immune response in
comparison with Alum (P < 0.05).
2.3.

Study the AdjuGel System and Determine If NMP Is Necessary for
Adjuvanticity

2.3.1. Introduction
In the previous studies, we demonstrated that ATBC and PLGA are indispensible
in the AdjuGel system as a vaccine adjuvant. Now we want to answer the question: is the
organic solvent NMP an essential component in the AdjuGel system for adjuvanticity.
The organic solvent NMP has been used in some of FDA approved drugs, but it belongs
to the class of dipolar aprotic solvents and may induce acute myotoxicity and local
inflammation,[51] which may help in the adjuvanticity of the Adjugel system. In the new
experiment, we used Triethyl Citrate (TEC), a relatively more hydrophobic liquid, to
replace NMP as solvent in AdjuGel system.
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Table 2-4.
The results of serum anti-OVA IgG antibody titers for group 1, 2, 3, 4, 5, 6, 7 and 8 at different time points of
day 0, week 2, 4, 6 and 8.
Time
G1
G2
G3
G4
G5
G6
G7
Day 0
0±0
0±0
0±0
0±0
0±0
0±0
0±0
2 weeks
0.34±0.42
0.1±0
0.67±0.43
0.1±0
0.34±0.42
0.26±0.28
0.1±0
4 weeks
0.31±0.37
0.1±0
0.69±0.33
0.1±0
0.31±0.37
0.29±0.33
0.1±0
6 weeks
0.17±0.12
0.1±0
0.55±0.35
0.1±0
0.17±0.12
0.24±0.24
0.1±0
8 weeks
0.27±0.29
0.1±0
0.63±0.53
0.1±0
0.27±0.29
0.16±0.1
0.1±0
P value
(6 weeks)
Serum anti-OVA IgG antibody titers were reported with Log10EC50 and results were presented as Mean ± S.D.
P value with 6 weeks results (*G3 vs. G8)
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G8
0±0
0.74±0.42
1.41±0.19
1.48±0.22
1.29±0.25
0.025*

Figure 2-5.

Rabbit serum anti-OVA IgG titers with multiple time points.
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2.3.2. Experimental procedures
2.3.2.1.

Materials

Nine white New Zealand female rabbits were ordered from Myrtles Rabbitry.
The biodegradable polymer PLGA was ordered from Lactel Absorbable Polymers,
Durect Corporation, Pelham, AL, USA. Triethyl Citrate (TEC) was obtained from
Morflex Inc, Greensboro, NC, USA; Lyophilized bovine serum albumin (BSA) as the
antigen was purchased from Sigma; Alum was ordered from Thermo Scientific.
Triethyl Citrate (TEC) is a colorless, odorless oily liquid, which is relatively more
hydrophobic than NMP. In this experiment, we used TEC to replace NMP as organic
solvent. The chemical structure of TEC is showed below (Figure 2-6).
2.3.2.2.

Formulation process

Formulation process of the BSA vaccine (all steps were prepared aseptically): 1.
Prepare a blank gel consisting of a blend of PLGA and a combination of TEC and ATBC
AT #-#  !N APPROPRIATE QUANTITY OF GEL WAS WEIGHED AND transferred in to an
autoclaved clean glass vial. An appropriate quantity of BSA was weighed and blended
with the gel and resulting mixture was stirred to obtain uniform mixture of BSA-loaded
gel. 3. Each dose of BSA-loaded gel contains 100ug of BSA per 0.5ml gel. The final
formulation is a suspension of BSA in the clear gel solution.
2.3.2.3.

Immunization of animals

For all the immunization experiments, Lyophilized BSA protein was dissolved in
PBS buffer or was suspended in AdjuGel system with organic solvent TEC immediately
before injection to obtain a concentration of 200ug/ml. All rabbits were given single IM
inoculation at day 0. Experimental assignment was shown in Table 2-5.
2.3.2.4.

Procedure

All groups were inoculated IM once at day 0 and blood samples were collected
every 2 weeks. Blood samples were serially diluted with 0.05% Tween 20 in PBS:
1:1,000, 1:10,000, 1:100,000 and 1:1,000,000. IgG titers were checked by ELISA
(Enzyme-Linked Immunosorbant Assay); use Log10EC50 as a measure of immune
response. EC50 means half maximal effective concentration and the absorbance of
1:1000 dilution was used as the maximum.
2.3.2.5.

Enzyme linked immunosorbent assay (ELISA)

96-well microtiter plates (high protein binding plates from Costar) were coated
overnight with 100 μl coating solution containing 3 μg/mL Bovine Serum Albumin
(BSA) at 4 ϶C. To remove unbound BSA, plates were washed three times with PBS (pH
7.4) containing 0.05% Tween 20 (PBST). Serum samples (100 μL/ well) from individual
rabbit were serially diluted in PBST: 1:1,000, 1:10,000, 1:100,000 and 1:1,000,000. The
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Figure 2-6.

Chemical structure of TEC.
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Table 2-5.

Rabbit experimental group assignment in BSA study.

Group Treatment

Number of Description
rabbits
1
Control
3
IM injection with PBS buffer and
BSA
2
ALUM+BSA
3
IM injection with ALUM and BSA
3
TEC+PLGA+ATBC+BSA
3
IM injection with TEC and ATBC
(2:1 V/V) plus PLGA and BSA
TEC (Triethyl Citrate) is a relatively more hydrophobic solvent when compared with
NMP. BSA is 100ug per injection. The volume is 0.5ml per injection.
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plates were then incubated for two hours at room temperature. The plates were again
washed three times with PBST followed by addition of 100 μL of PBST containing
Horseradish Peroxidase (HRP) -conjugated goat anti-rabbit IgG (diluted 1:4000) (Abcam,
ab6721). After a two hour incubation period at room temperature, the plates were washed
three times with PBST followed by the addition of 200 μL of 0.4 mg/ml OPD Peroxidase
Substrate (Sigma P9187, Sigma-Aldrich, St. Louis, MO) and allowed to react for 30
minutes at room temperature. The optical density (OD) of the reaction was measured at
450 nm using a Plate Reader. Software BioDataFit was applied to deal with the data by
the four-parameter model. Serum titers are reported with Log10EC50.
2.3.2.6.

Statistical analysis

Results are expressed as mean ± S.D. Statistical analysis was carried out for
analyses of differences between means of serum antibody titers using Student’s twotailed t-test. Differences in means were accepted as significant if P was less than 0.05.
2.3.3. Results and discussion
Serum titers were reported with Log10EC50 and results was showed in Table 2-6
and Figure 2-7.
From the results we could see that even we used a more hydrophobic organic
solvent, instead of NMP, the AdjuGel system can still induce strong immune response. At
time point of week 4, there is significant difference between group 3, composed of TEC,
PLGA and ATBC, and group 1(negative control) (P < 0.05).
2.3.4. Conclusion
In the AdjuGel system, organic solvent NMP is replaceable and other more
hydrophobic solvents could be used in this system.
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Table 2-6.
The results of serum anti-BSA IgG antibody titers for group 1, 2 and
3 at different time points of day 0, week 2, 4, 6 and 8.
Time
G1
G2
G3
Day 0
0±0
0±0
0±0
2 weeks
0.91±0.7
1.42±0.25
0.92±0.38
4 weeks
0.64±0.49
1.18±0.04
1.68±0.32
6 weeks
0.78±0.59
1.27±0.21
1.58±0.26
8 weeks
0.48±0.42
0.96±0.22
1.36±0.34
P value
(4 weeks)
0.044*
Serum anti-BSA IgG antibody titers were reported with Log10EC50 and results were
presented as Mean ± S.D.
P value with 4 weeks results (*G3 vs. G1)
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Figure 2-7.

Rabbit serum anti-BSA IgG titers with multiple time points.
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CHAPTER 3. DEVELOPMENT OF NEW VACCINE FORMULATIONS WITH
DELAYED IMMUNE RESPONSE BASED ON ADJUGEL SYSTEM USING
ORGANIC SOLVENT NMP
3.1.

Introduction

From the three experiments in Chapter 2, we could draw the conclusion that the
AdjuGel system is a new type of vaccine adjuvant or delivery system, which has
significant potential for sustained release activity and development of single dose
vaccines.
The Oil-based formulations are one of the most classic formulations in vaccine
adjuvants. Previous studies showed neither oils nor surfactants alone can induce strong
immune responses.[5] we compared the oil- based vaccine adjuvants to the AdjuGel
system and found the AdjuGel system displayed a similar mode of action to oil-based
vaccine adjuvants. In AdjuGel systems, ATBC could be considered the oil and polymer
PLGA could be considered the surfactant. Just like oil-based adjuvants, removal of either
ATBC or Polymer PLGA could lead to the loss of strong immune response. However, the
hydrophobic polymer PLGA is not a surfactant. Under normal conditions, PLGA will
not act as a surfactant because of the high molecular weight. When exposed to aqueous
media such as PBS buffers or tissues, hydrophobic polymer PLGA or PLA will absorb
water and ester linkages will break by hydrolysis, which leads long polymer chains to
break into shorter ones. As a result, the reduction in molecular weight produces an
increase in hydrophilicity. When the hydrophilicity lipophilicity balance (HLB) of
polymer reaches a suitable scale, hydrophobic polymer PLGA or PLA will show the
characteristics of surfactants, which in turn may alter the AdjuGel system to be more
similar to classic oil-based vaccine adjuvant and induce immune responses.
Based on the hypothesis above, AdjuGel system should exhibit a delayed immune
response because degradation of PLGA polymer will need some time in vivo. However,
in the rabbit experiment, we did not see a delayed response. The reason is probably
because of the intramuscular administration route. Injected into muscular tissues, the ISI
system will be degraded very fast. Limited space in muscle prevents ISI system from
forming a single implant with integrity. Also plenty of blood circulation in muscular
tissues causes a high rate of metabolism, which also accelerates the degradation of PLGA
polymer. So there is no delayed response demonstrated in the rabbit experiment. In order
to slow the degradation rate, we chose to use a subcutaneous injection instead of
intramuscular injection.
For the new animal experiment, two different PLGA polymers were chosen to test
if they could provide delayed immune responses. The first one is a relatively hydrophilic
and fast degradation polymer; the second PLGA polymer is a more hydrophobic and slow
degradation polymer. We predicted that the formulation with second PLGA polymer
could provide a delay immune response compared to the formulation with first PLGA
polymer.
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Because AdjuGel system is a new formulation for vaccine adjuvant, type of
immunity (humoral or cell mediate immunity) need to be determined. It’s well known
that Alum will initiate humoral immune response (Th2 response) rather than cell mediate
immune response (Th1 response). [52] We used Alum as control and measured total IgG
titers, isotype IgG1 titers (represent humoral immunity) and isotype IgG2a titers
(represent cell mediate immunity) in the new experiment.
3.2.

Experimental Procedures

3.2.1. Materials
35 BABL/c female mice (6-8 weeks) were ordered from Jackson Lab. The
biodegradable polymer PLGA was ordered from Lactel Absorbable Polymers, Durect
Corporation, Pelham, AL, USA. NMP was obtained from ISP Pharm Technologies;
Acetyl Tributyl Citrate (ATBC) was obtained from Morflex Inc, Greensboro, NC, USA;
Lyophilized Ovalbumin (OVA) as the antigen was purchased from Sigma; Alum was
ordered from Thermo Scientific.
3.2.2. Methods
Formulation process of the vaccines (all steps were prepared aseptically): 1.
Prepare four groups of AdjuGels consisting of a blend of PLGA and a combination of
.-0 AND !4"# AT #-# 2. An appropriate quantity of gel was weighed and
transferred in to an autoclaved clean glass vial. An appropriate quantity of OVA was
weighed and blended with the gel and resulting mixture was stirred to obtain uniform
mixture of OVA-loaded gel. 3. Each dose of OVA-loaded gel contains 50ug of OVA per
0.1ml gel. The final formulation is a suspension of OVA in the clear gel solution.
3.2.2.1.

In vitro studies

One mililiter of each vaccine gel (formulations are same with group 4, 5, 6 and 7
below) was loaded into a 20ml autoclaved clean bottle, and then 4.0 ml PBS (pH 7.4,
0.01 M) was added. The sample bottles were kept in 37°C shaker at 60 rpm. At 24 hrs
and then at two days and one week intervals, 3.0 ml PBS sample was collected and
analyzed for ovalbumin and ATBC concentration with Enzyme immunoassay (EIA) and
high performance liquid chromatograph (HPLC) method. 3.0 ml fresh PBS was added
after every collection. Release profiles were calculated by cumulative release with
incubation time.
3.2.2.1.1.

Analytical method development for OVA (EIA)

96-well microtiter plates (high protein binding plates from Costar) were coated
overnight with 100 μl of ovalbumin standard solutions and samples for test at 4 ϶C. To
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remove unbound OVA, plates were washed three times with PBS (pH 7.4) containing
0.05% Tween 20 (PBST). Primary antibody from rabbit were diluted in PBST and loaded
into the plates with 100 μL/ well. The plates were then incubated for two hours at room
temperature. The plates were again washed three times with PBST followed by addition
of 100 μL of PBST containing Horseradish Peroxidase (HRP) -conjugated goat antirabbit IgG (diluted 1:4000) (Abcam, ab6721). After a two hour incubation period at room
temperature, the plates were washed three times with PBST followed by the addition of
200 μL of 0.4 mg/ml OPD Peroxidase Substrate (Sigma P9187, Sigma-Aldrich, St. Louis,
MO) and allowed to react for 30 minutes at room temperature. The optical density (OD)
of the reaction was measured at 450 nm using a Plate Reader. The sample OVA
concentrations were calculated in accordance to standard curve.
3.2.2.1.2.

Analytical method development for ATBC (HPLC)

ATBC was analyzed by reverse phase (RP)-HPLC using a C18 column, 150 mm
× 4.60 mm (SGE Analytical Science. Part No. 250112). The mobile phase was a 7:3
mixture of acetonitrile (HPLC grade) and water (HPLC grade). The flow rate was set at
1ml/min and the injector volume was 50 μm. UV absorbance was measured at 234 nm
using a photodiode array detector equipped with the high performance liquid
chromatography system (HPLC). The results were calculated based on the readings from
a standard series of ATBC. [53]
3.2.2.2.

Immunization of animals

For all the immunization experiments, Lyophilized OVA protein was dissolved in
PBS buffer or was suspended in different AdjuGel systems with organic solvent NMP
immediately before injection to obtain a concentration of 500ug/ml. All mice were given
single S.C. inoculation in lower back at day 0. Experimental assignment was shown in
Table 3-1.
3.2.2.3.

Procedures

All groups were inoculated S. C. once at day 0 and blood samples were collected
every 2 weeks in the first 2 months and every 3 or 4 weeks thereafter. Blood samples
were serially diluted with 0.05% Tween 20 in PBS: 1:100, 1:1,000, 1:10,000 and
1:100,000. IgG titers were checked by ELISA (Enzyme-Linked Immunosorbant Assay);
use Log10EC50 as a measure of immune response. EC50 means half maximal effective
concentration and the absorbance of 1:100 dilution was used as the maximum.
3.2.2.4.

Enzyme linked immunosorbent assay (ELISA)

96-well microtiter plates (high protein binding plates from Costar) were coated
overnight with 100 μl coating solution containing 3 μg/mL ovalbumin (OVA) at 4 ϶C. To
remove unbound OVA, plates were washed three times with PBS (pH 7.4) containing
0.05% Tween 20 (PBST). Serum samples (100 μL/ well) from individual mice were
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Table 3-1.

Mouse experimental group assignment in OVA study.

Group Treatment
1
2

Number Description
of mouse
5
S.C. injection with PBS buffer and OVA
5
S.C. injection ATBC emulsion and OVA

Control
ATBC emulsion
+OVA
3
ALUM+OVA
5
S.C. injection with ALUM and OVA
4
AdjuGel 1 + OVA
5
S.C. injection with AdjuGel 1 and OVA
5
AdjuGel 2 +OVA
5
S.C. injection with AdjuGel 2 and OVA
6
AdjuGel 3 +OVA
5
S.C. injection with AdjuGel 3 and OVA
7
AdjuGel 4 +OVA
5
S.C. injection with AdjuGel 4 and OVA
Ovalbumin is 50ug per injection. The volume is 100ul per injection.
AdjuGel 1: NMP, ATBC and low molecular weight PLGA (50:50; IV: 0.65). The ATBC
concentration is 30% (w/w).
AdjuGel 2: NMP, ATBC and low molecular weight PLGA (50:50; IV: 0.65). The ATBC
concentration is 15% (w/w).
AdjuGel 3: NMP, ATBC and high molecular weight PLGA (85:15; IV: 0.65). The
ATBC concentration is 30% (w/w).
AdjuGel 4: NMP, ATBC and high molecular weight PLGA (85:15; IV: 0.65). The
ATBC concentration is 15% (w/w).
The PLGA concentration in AdjuGel 1, AdjuGel 2, AdjuGel 3 and AdjuGel 4 is 20%
(w/w).
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serially diluted in PBST: 1:100, 1:1,000, 1:10,000 and 1:100,000. The plates were then
incubated for two hours at room temperature. The plates were again washed three times
with PBST followed by addition of 100 μL of PBST containing Horseradish Peroxidase
(HRP) -conjugated Goat Anti-Mouse IgG (diluted 1:4000) (Abcam, ab6789), or
Horseradish Peroxidase (HRP) -conjugated Goat Anti-Mouse IgG1 (diluted 1:4000)
(Abcam, ab97240) or Horseradish Peroxidase (HRP) -conjugated Goat Anti-Mouse
IgG2a (Abcam, ab97241). After a two hour incubation period at room temperature, the
plates were washed three times with PBST followed by the addition of 200 μL of 0.4
mg/ml OPD Peroxidase Substrate (Sigma P9187, Sigma-Aldrich, St. Louis, MO) and
allowed to react for 30 minutes at room temperature. The optical density (OD) of the
reaction was measured at 450 nm using a Plate Reader. Software BioDataFit was applied
to deal with the data by the four-parameter model. Serum titers are reported with
Log10EC50.
3.2.2.5.

Statistical analysis

Results are expressed as mean ± S.D. Statistical analysis was carried out for
analyses of differences between means of serum antibody titers using Student’s twotailed t-test. Differences in means were accepted as significant if P was less than 0.05.
3.3.

Results

3.3.1. In vitro release- Ovalbumin
The study of OVA In vitro release showed that the four AdjuGel groups could
provide continuous sustained release of OVA (Table 3-2 and Figure 3-1). In the groups
of low molecular weight PLGA, OVA could be released up to seven weeks; in the groups
of high molecular weight PLGA, OVA could be released up to thirteen weeks. The high
concentration of ATBC could decrease initial burst release of OVA because ATBC
increased hydrophobicity in the AdjuGel groups, which in turn decrease OVA initial
burst release. However, the high concentration of ATBC didn’t prolong the whole release
period. There are burst releases in all AdjuGel groups. On day 3, 10% of total ovalbumin
was released in group AdjuGel 1; 24% of total ovalbumin was released in group AdjuGel
2; 11% of total ovalbumin was released in group AdjuGel 3; 14% of total ovalbumin was
released in group AdjuGel 4.
3.3.2. In vitro release- ATBC
The study of ATBC in vitro release showed that the four AdjuGel groups could
provide delayed release of ATBC (Table 3-3 and Figure 3-2). In the groups of low
molecular weight PLGA, ATBC wouldn’t be released significantly until the fifth weeks;
in the groups of high molecular weight PLGA, ATBC wouldn’t be released significantly
until the tenth weeks.
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Table 3-2.

Data of in vitro OVA accumulative release with four AdjuGel groups.

Time
AdjuGel 1
AdjuGel 2
AdjuGel 3
AdjuGel 4
Day 0
0±0
0±0
0±0
0±0
Day 1
0.06±0.03
0.12±0.02
0.05±0.03
0.07±0.01
Day 3
0.1±0.02
0.24±0.06
0.11±0.02
0.14±0.01
Week 1
0.13±0.01
0.42±0.17
0.18±0.03
0.33±0.06
Week 2
0.16±0.02
0.57±0.07
0.27±0.04
0.44±0.04
Week 3
0.33±0.03
0.73±0.05
0.44±0.16
0.57±0.05
Week 4
0.75±0.08
0.87±0.05
0.58±0.16
0.64±0.03
Week 5
0.9±0.02
0.95±0.03
0.63±0.02
0.68±0.01
Week 6
0.95±0
0.98±0.01
0.67±0.02
0.73±0.01
Week 7
1±0.01
1±0.01
0.75±0.01
0.81±0.01
Week 8
0.83±0.01
0.88±0.02
Week 9
0.88±0
0.93±0.01
Week 10
0.92±0
0.96±0.01
Week 11
0.96±0
0.98±0.01
Week 12
0.98±0
0.99±0
Week 13
1±0
1±0
AdjuGel 1: NMP, ATBC and low molecular weight PLGA (50:50; IV: 0.65). The ATBC
concentration is 30% (w/w); AdjuGel 2: NMP, ATBC and low molecular weight PLGA
(50:50; IV: 0.65). The ATBC concentration is 15% (w/w); AdjuGel 3: NMP, ATBC and
high molecular weight PLGA (85:15; IV: 0.65). The ATBC concentration is 30% (w/w);
AdjuGel 4: NMP, ATBC and high molecular weight PLGA (85:15; IV: 0.65). The
ATBC concentration is 15% (w/w). Data were presented as Mean ± S. D.
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Figure 3-1. In vitro OVA release study with four AdjuGel groups.
AdjuGel 1: NMP, ATBC and low molecular weight PLGA (50:50; IV: 0.65). The ATBC
concentration is 30% (w/w); AdjuGel 2: NMP, ATBC and low molecular weight PLGA
(50:50; IV: 0.65). The ATBC concentration is 15% (w/w); AdjuGel 3: NMP, ATBC and
high molecular weight PLGA (85:15; IV: 0.65). The ATBC concentration is 30% (w/w);
AdjuGel 4: NMP, ATBC and high molecular weight PLGA (85:15; IV: 0.65). The
ATBC concentration is 15% (w/w).
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Table 3-3.
groups.

Data of in vitro ATBC accumulative release with four AdjuGel

Time
AdjuGel 1
AdjuGel 2
AdjuGel 3
AdjuGel 4
Day 0
0±0
0±0
0±0
0±0
Day 1
0.0004±0.0007 0.0004±0.0001 0.0002±0.0001 0.0004±0.0001
Day 3
0.0007±0
0.0007±0
0.0005±0
0.0008±0.0001
Week 1
0.001±0
0.0011±0
0.0007±0
0.0012±0.0003
Week 2
0.0013±0
0.0014±0
0.0009±0
0.0015±0
Week 3
0.0015±0
0.0018±0.0001
0.0011±0
0.0019±0.0002
Week 4
0.0018±0
0.0022±0.0002
0.0014±0
0.0023±0.0001
Week 5
0.2506±0.3838 0.1341±0.3741 0.0023±0.0005 0.0028±0.0007
Week 6
0.5585±0.3067 0.3531±0.2777 0.0033±0.0012
0.0031±0
Week 7
1±0.3087
1±0.3476
0.0038±0.0002 0.0038±0.0017
Week 8
0.0222±0.1081 0.0069±0.0454
Week 9
0.0246±0.0043 0.0094±0.0026
Week 10
0.0945±0.258 0.0234±0.1503
Week 11
0.1079±0.0355 0.0308±0.0532
Week 12
0.2857±0.3498 0.1137±0.425
Week 13
1±0.2423
0.9998±0.3204
AdjuGel 1: NMP, ATBC and low molecular weight PLGA (50:50; IV: 0.65). The ATBC
concentration is 30% (w/w); AdjuGel 2: NMP, ATBC and low molecular weight PLGA
(50:50; IV: 0.65). The ATBC concentration is 15% (w/w); AdjuGel 3: NMP, ATBC and
high molecular weight PLGA (85:15; IV: 0.65). The ATBC concentration is 30% (w/w);
AdjuGel 4: NMP, ATBC and high molecular weight PLGA (85:15; IV: 0.65). The
ATBC concentration is 15% (w/w). Data were presented as Mean ± S. D.
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Figure 3-2. In vitro ATBC release study with four AdjuGel groups.
AdjuGel 1: NMP, ATBC and low molecular weight PLGA (50:50; IV: 0.65). The ATBC
concentration is 30% (w/w); AdjuGel 2: NMP, ATBC and low molecular weight PLGA
(50:50; IV: 0.65). The ATBC concentration is 15% (w/w); AdjuGel 3: NMP, ATBC and
high molecular weight PLGA (85:15; IV: 0.65). The ATBC concentration is 30% (w/w);
AdjuGel 4: NMP, ATBC and high molecular weight PLGA (85:15; IV: 0.65). The
ATBC concentration is 15% (w/w).
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3.3.3. In vivo studies
48 hrs after S.C. injection, all mice in group 4, 5, 6 and 7 showed mild to
moderate skin lesions (local inflammatory reaction at the injection sites). The reason is
not very clear although it is probably related to NMP. The skin lesions were recovered
within two weeks after treatment with antibiotic ointment.
The IgG titers in all AdjuGel groups showed significantly greater than those in the
negative control (group 1) between week 4 and week 8 (P <0.05, Table 3-4 and Figure
3-3). But there was no significant difference between AdjuGel groups and the positive
controls (group 2 and 3) between week 4 and week 8 (P >0.05). Also the AdjuGel groups
didn’t show any delayed immune responses, but showed normal immune responses
profiles similar to positive controls.
The IgG1 titers in all AdjuGel groups showed significantly greater than those in
the negative control (group 1) between week 4 and week 8 (P < 0.05, Table 3-5 and
Figure 3-4). However, the AdjuGel groups didn’t show any delayed immune responses,
but showed normal immune responses profiles similar to positive controls.
The IgG2a titers of all groups were very low and no significant difference among
them from week 4 to week 8 (Table 3-6 and Figure 3-5).

3.4.

Discussion

Even though a delayed ATBC release was presented in in vitro study, the in vivo
mouse studies clearly showed the immune response was detected in two weeks, which
means that there was probably no delayed ATBC release in vivo.
Why is there a difference between the in vitro and in vivo results?
From the local inflammation in the injection sites and surrounding skin lesions,
we believed the organic solvent N-Methyl-2-pyrrolidone (NMP) is the key component
which induced the inflammation and may accelerate the degradation of PLGA polymer,
which in turn could cause the fast immune responses right after the injections.
NMP was used in some FDA approved drugs, such as Eligard® (leuprolide acetate for in
situ implant depot). In 1998 a study with rhesus monkeys showed that NMP is a safe
organic solvent in a drug delivery system. [54] Our previous rabbit experiment also did
not show any side effects with the injection of gel formulations containing NMP.
Although NMP seemed safe in the experiments of monkey and rabbit, it displayed pretty
strong tissue irritation and caused local inflammation at the injection sites in our mouse
study. In 2001, Kranz and his colleagues studied three biocompatible organic solvents:
NMP, DMSO and 2-pyrrolidone for the acute toxicity or tissue damage following
intramuscular injection with rats.[50] They found the rank order of tissue damage of the
solvents was 2-pyrrolidone< DMSO< NMP. (See Figure 3-6 below)[50]
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Table 3-4.
The results of serum anti-OVA IgG antibody titers for group 1, 2, 3, 4, 5, 6 and 7 at different time points of day
0, week 2, 4, 6, 8, 11, 14 and 18.
Time
G1
G2
G3
G4
G5
G6
Day 0
0± 0
0± 0
0± 0
0± 0
0± 0
0± 0
2 weeks
0.18± 0.05
0.81± 0.14
0.56± 0.21
0.83± 0.24
0.43± 0.31
1.01± 0.51
4 weeks
0.28± 0.15
0.92± 0.14
0.94± 0.25
0.91± 0.43
0.59± 0.5
1.14± 0.5
6 weeks
0.35± 0.13
0.88± 0.2
1.03± 0.19
0.73± 0.78
1.23± 0.5
1.24± 0.76
8 weeks
0.4± 0.27
0.99± 0.16
1.18± 0.5
1± 0.69
0.88± 1.09
1.32± 0.79
11 weeks
0.34± 0.29
0.98± 0.23
1.19± 0.22
0.72± 0.5
1.26± 0.74
14 weeks
0.63± 0.31
1.03± 0.31
1.14± 0.3
0.71± 0.54
1.13± 0.73
18 weeks
0.2± 0
0.38± 0.1
0.38± 0.1
0.4± 0.2
0.58± 0.25
P value
0.693*
0.347**
0.422***
Serum anti-OVA total IgG titers were reported with Log10EC50 and data were presented as Mean ± S. D.
P values with 6 weeks results (*G4 vs. G2; **G5 vs. G2; ***G6 vs. G2; ****G7 vs. G2)
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G7
0± 0
0.66± 0.35
0.79± 0.47
0.84± 0.49
0.88± 0.67
1± 0.75
0.91± 0.67
0.6± 0.3
0.884****
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Figure 3-3. Mice serum anti-OVA IgG antibody titers.
G1, S.C. injection with PBS buffer and OVA; G2, S.C. injection ATBC emulsion and
OVA; G3, S.C. injection with ALUM and OVA; G4, S.C. injection with AdjuGel 1 and
OVA; G5, S.C. injection with AdjuGel 2 and OVA; G6, S.C. injection with AdjuGel
3 and OVA; G7, S.C. injection with AdjuGel 4 and OVA.
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Table 3-5.
The results of serum anti-OVA IgG1 antibody titers for group 1, 2, 3, 4, 5, 6 and 7 at different time points of day
0, week 2, 4, 6, 8, 11, 14 and 18.
Time
G1
G2
G3
G4
G5
Day 0
0±0
0±0
0±0
0±0
0±0
2 weeks
0.15±0.06
0.82±0.26
0.69±0.28
0.77±0.38
0.37±0.29
4 weeks
0.23±0.12
0.98±0.09
0.96±0.31
1.02±0.62
0.61±0.63
6 weeks
0.38±0.17
0.95±0.21
1.16±0.25
0.73±0.8
1.75±0.13
8 weeks
0.41±0.31
1.03±0.26
1.26±0.47
1.06±0.75
0.91±1.16
11 weeks
0.32±0.31
1.06±0.2
1.34±0.23
0.79±0.62
14 weeks
0.68±0.37
1.14±0.34
1.26±0.34
0.78±0.73
18 weeks
0.1±0
0.3±0.1
0.3±0.1
0.4±0.2
Serum anti-OVA IgG1 titers were reported with Log10EC50 and data were presented as Mean ± S. D.

49

G6
0±0
1.17±0.54
1.26±0.49
1.38±0.81
1.43±0.82
1.3±0.84
1.22±0.75
0.45±0.25

G7
0±0
0.7±0.38
0.85±0.63
0.87±0.56
0.93±0.72
1.02±0.81
0.98±0.76
0.55±0.35

2.5

2
G1
G2

Anti-OVA IgG1 Titers

1.5

G3
G4
G5

1

G6
G7

0.5

0
Day 0

2 weeks 4 weeks 6 weeks 8 weeks 11 weeks 14 weeks 18 weeks

Figure 3-4. Mice serum anti-OVA IgG1 antibody titers.
G1, S.C. injection with PBS buffer and OVA; G2, S.C. injection ATBC emulsion and
OVA; G3, S.C. injection with ALUM and OVA; G4, S.C. injection with AdjuGel 1 and
OVA; G5, S.C. injection with AdjuGel 2 and OVA; G6, S.C. injection with AdjuGel
3 and OVA; G7, S.C. injection with AdjuGel 4 and OVA.
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Table 3-6.
The results of serum anti-OVA IgG2a antibody titers for group 1, 2, 3, 4, 5, 6 and 7 at different time points of
day 0, week 2, 4, 6 and 8.
Time
G1
G2
G3
G4
G5
G6
Day 0
0±0
0±0
0±0
0±0
0±0
0±0
2 weeks
0.06±0.005
0.06±0.008
0.07±0.029
0.17±0.12
0.06±0.006
0.06±0
4 weeks
0.06±0.005
0.07±0.009
0.07±0.013
0.06±0.011
0.06±0.006
0.08±0.012
6 weeks
0.06±0.005
0.09±0.025
0.1±0.021
0.07±0.005
0.1±0.01
0.1±0.007
8 weeks
0.06±0.006
0.1±0.026
0.1±0.046
0.1±0.035
0.08±0.034
0.12±0.065
Serum anti-OVA IgG2a titers were reported with Log10EC50 and data were presented as Mean ± S. D.
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G7
0±0
0.06±0.008
0.07±0.008
0.07±0.019
0.11±0.068
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Figure 3-5. Mice serum anti-OVA IgG2a antibody titers.
G1, S.C. injection with PBS buffer and OVA; G2, S.C. injection ATBC emulsion and
OVA; G3, S.C. injection with ALUM and OVA; G4, S.C. injection with AdjuGel 1 and
OVA; G5, S.C. injection with AdjuGel 2 and OVA; G6, S.C. injection with AdjuGel
3 and OVA; G7, S.C. injection with AdjuGel 4 and OVA.
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Figure 3-6. Cumulative CK-release following the injection of Nmethyl-2pyrrolidone (NMP), dimethylsulfoxide (DMSO), 2-pyrrolidone, phenytoin (positive
control) and 0.9% NaCl (negative control). (Reprinted with permission: Kranz, H., et
al., Myotoxicity studies of injectable biodegradable in-situ forming drug delivery systems. Int
J Pharm, 2001. 212(1): p. 11-8.)
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From the published data and our studies, it seems organic solvent NMP is
relatively safe for big animals like monkey and rabbit, but can be toxic for small ones like
rat and mouse. In the former studies we drew conclusion that organic solvent NMP is
replaceable and other more hydrophobic solvents could be used in the AdjuGel system.
(In Chapter 2) So we determined to find a safer and less irritating organic solvent for
AdjuGel system.
According to FDA Q3C guideline,[55] organic solvent NMP belongs to class 2,
which was defined as “non-genotoxic animal carcinogens or possible causative agents of
irreversible toxicity, such as neurotoxicity or teratogenicity”.[56] In order to decrease
local inflammation and improve the biocompatibility, we started to screen the solvents in
class 3 since they are much safer than the solvents in class 2.
After carefully screening the organic solvent lists in class 3, ethyl acetate (EA)
became a good choice of organic solvent since not only it could increase hydrophobicity
but also decrease viscosity in AdjuGel system. In 2008, Rungseevijitprapa and his
colleagues studied organic solvents ethyl acetate, benzyl alcohol, triethyl citrate,
propylene carbonate and triacetin for the acute toxicity or tissue damage following
intramuscular injection with rats.[51] They found the rank order of tissue damage of the
solvents was ethyl acetate< propylene carbonate < triacetin<triethyl citrate< benzyl
alcohol. (See Figure 3-7 below) Ethyl acetate showed low toxic potential, which is
similar to isotonic normal saline (0.9% NaCl)[51]
Because of the data above, we determined to choose ethyl acetate instead of NMP
in AdjuGel system for further studies.
Based on the results, we can clearly see that the AdjuGel system exhibited similar
immune response profiles to that seen with the positive controls, Alum and ATBC
emulsion. They all exhibited relatively high IgG1 titers but very low IgG2a titers, which
suggest that the tested formulation can induce effective humoral immunity, but fail to
induce good cell mediated immune responses, or suggest the absence of a T helper cell
type 1 (Th1) response. Other immunopotentiators should be added if cell mediated
immune responses are necessary.
3.5.

Conclusion

From the data above, we concluded that: 1. Organic solvent NMP demonstrated
toxicity to mice after subcutaneous injection and induced inflammation at the injection
sites. 2. AdjuGel system, comprised of NMP, PLGA and ATBC, induce strong Th2
response with little or no Th1 response, which is similar to classic oil-based adjuvant and
Alum adjuvant. 3. Although AdjuGel system, comprised of NMP, PLGA and ATBC,
showed delayed release of ATBC in vitro, it didn’t demonstrate delayed immune
response in vivo.
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Figure 3-7. Cumulative CK release after 120 min following the injection of
undiluted solvents in comparison to the positive control (phenytoin) and the
negative control (0.9% NaCl). (Reprinted with permission: Rungseevijitprapa, W., et al.,
Myotoxicity studies of O/W-in situ forming microparticle systems. Eur J Pharm Biopharm,
2008. 69(1): p. 126-33.)
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CHAPTER 4. DEVELOPMENT OF NOVEL FORMULATIONS WITH
DELAYED IMMUNE RESPONSE BASED ON ADJUGEL SYSTEM USING
ORGANIC SOLVENT ETHYL ACETATE
4.1.

Introduction

Pulsatile release formulations for single dose vaccines have been studied for many
years because of the advantages that they may simulate the vaccine administration with
prime and booster shots. The most important key point in the formulation design is how
to realize the delayed response and control the time window of booster response. General
strategy was focused on programmed delay release of antigens in order to induce the
delayed booster response. [47] Although the programmed delay release of antigens could
be realized in vitro, the delayed release of antigens in vitro doesn’t equal to delayed
immune response in vivo. Until now, none of vaccine delivery systems achieved delayed
immune response in vivo. We tried to approach this goal by designing new vaccine
delivery system with delayed release of both antigen and vaccine adjuvant. Considering
the functions of vaccine adjuvant in subunit vaccines, we believe that the delayed release
of vaccine adjuvant is probably more important than the delayed release of antigen for
delayed immune responses. In the AdjuGel system, the oil, ATBC and Hydrophobic
polymer PLGA are the key components for immune response. Because ATBC is a
plasticizer for PLGA polymer, it can interpose between individual strands of polymer to
form a miscible condition with solidified polymer. Under such structure, the polymer can
hold the plasticizer ATBC and ATBC won’t be release until polymer starts to degrade. So
the release of ATBC and PLGA is determined by the degradation of polymer PLGA.
Organic solvent ethyl acetate is the ester of ethanol and acetic acid. It is a safe solvent
with low toxicity. After intramuscular injection in rats, it showed similar acute toxicity or
tissue damage to isotonic normal saline (0.9% NaCl).[51] Additionally, ethyl acetate is
relatively more hydrophobic solvent compared to NMP. Its solubility in water is 8.3
g/100 mL in 20 °C and NMP is miscible with water. The hydrophobicity of ethyl acetate
may help to decrease the burst release of antigen proteins in the AdjuGel system. The
burst release of antigen proteins may contribute to the fast response of AdjuGel groups in
the previous experiment. Not only ethyl acetate may decrease the burst release of antigen
proteins, but its hydrophobicity can also slow the degradation speed of PLGA polymer in
AdjuGel system, which will stabilize AdjuGel system and elongate the delayed period
before response.
4.2.

Experimental Procedures

4.2.1. Materials
Twenty ICR female mice (6-8 weeks) were ordered from Harlan Laboratories.
The biodegradable polymer PLGA and Polylactic acid (PLA) were ordered from Lactel
Absorbable Polymers, Durect Corporation, Pelham, AL, USA. Ethyl acetate was ordered
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from Fisher Scientific; Acetyl Tributyl Citrate (ATBC) was obtained from Morflex Inc,
Greensboro, NC, USA; Lyophilized Ovalbumin (OVA) as the antigen was purchased
from Sigma.
Two PLGA polymers, PLGA (50:50, lactic acid: glycolic acid) and PLGA (85:15,
lactic acid: glycolic acid) were used in the in vitro release study to compare the release
profiles of OVA and ATBC. Polymer PLGA (50:50, lactic acid: glycolic acid) is
relatively hydrophilic and polymer PLGA (85:15, lactic acid: glycolic acid) is relatively
hydrophobic.
Besides two PLGA polymers, polymer PLGA (100:0, lactic acid: glycolic acid) or
PLA was added in animal experiment to test the profiles of delayed immune response.
Polymer PLA is the most hydrophobic polymer among the three polymers.
Polylactic acid (PLA) is an aliphatic polyester. It is derived from renewable resources,
such as corn starch, tapioca roots, chips or starch or sugarcane. When used in a drug
delivery system, PLA has two different products: poly (L-lactide) and poly (DL-lactide).
Poly (DL-lactide) is the polymer we planned to use. It is from Polymerization of a
racemic mixture of L- and D-lactides and the approximately resorption time in vivo is 12
– 16 months. The chemical structure of poly (DL-lactide) is showed below (Figure 4-1).
Ethyl acetate is a colorless liquid has a characteristic sweet smell. It is an organic
solvent with the formula CH3-COO-CH2-CH3. In the experiment, we used ethyl acetate,
instead of NMP as organic solvent in the AdjuGel system. The chemical structure of
ethyl acetate is showed below (Figure 4-2).

4.2.2. Methods
Formulation process of the vaccines (all steps were prepared aseptically): 1.
Prepare three groups of AdjuGels consisting of a blend of PLGA or PLA and a
COMBINATION OF ETHYL ACETATE AND !4"# AT #-#  !N APPROPRIATE QUANTITY OF GEL
was weighed and transferred in to an autoclaved clean glass vial. An appropriate quantity
of OVA was weighed and blended with the gel and resulting mixture was stirred to obtain
uniform mixture of OVA-loaded gel. 3. Each dose of OVA-loaded gel contains 100ug of
OVA per 0.1ml gel.
4.2.3. In vitro studies
Two formulations of vaccine gel were prepared for in vitro release study.
Formulation one used 65% ethyl acetate (solvent), 20% PLGA (50:50, IV: 0.65), 15%
ATBC and 1mg/ml lyophilized ovalbumin. All ratios are weight to weight. Formulation
two used 65% ethyl acetate (solvent), 20% PLGA (85:15, IV: 0.65), 15% ATBC and
1mg/ml lyophilized ovalbumin. The only difference between the two formulations is the
polymers. Formulation one used a relatively hydrophilic polymer and formulation two
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Figure 4-1.

Chemical structure of poly (DL-lactide).
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Figure 4-2.

Chemical structure of ethyl acetate.
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used a relatively hydrophobic polymer.
0.5 ml of each vaccine gel (formulation one and two) was loaded into a bottle, and
then 3.0 ml PBS (pH 7.4, 0.01 M) was added. The sample bottles were kept in 37°C
shaker at 60 rpm. At 24 hr and then at two days and one week intervals, 2.0 ml PBS
sample was collected and analyzed for ovalbumin and ATBC concentration with Enzyme
immunoassay (EIA) and HPLC method. 2.0 ml fresh PBS was added after every
collection. Release profiles were calculated by cumulative release with incubation time.
4.2.3.1.

Analytical method development for OVA (EIA)

96-well microtiter plates (high protein binding plates from Costar) were coated
overnight with 100 μl of ovalbumin standard solutions and samples for test at 4 ϶C. To
remove unbound OVA, plates were washed three times with PBS (pH 7.4) containing
0.05% Tween 20 (PBST). Primary antibody from rabbit were diluted in PBST and loaded
into the plates with 100 μL/ well. The plates were then incubated for two hours at room
temperature. The plates were again washed three times with PBST followed by addition
of 100 μL of PBST containing Horseradish Peroxidase (HRP) -conjugated goat antirabbit IgG (diluted 1:4000) (Abcam, ab6721). After a two hour incubation period at room
temperature, the plates were washed three times with PBST followed by the addition of
200 μL of 0.4 mg/ml OPD Peroxidase Substrate (Sigma P9187, Sigma-Aldrich, St. Louis,
MO) and allowed to react for 30 minutes at room temperature. The optical density (OD)
of the reaction was measured at 450 nm using a Plate Reader. The sample OVA
concentrations were calculated in accordance to standard curve.
4.2.3.2.

Analytical method development for ATBC (HPLC)

ATBC was analyzed by reverse phase (RP)-HPLC using a C18 column, 150 mm
× 4.60 mm (SGE Analytical Science. Part No. 250112). The mobile phase was a 7:3
mixture of acetonitrile (HPLC grade) and water (HPLC grade). The flow rate was set at
1ml/min and the injector volume was 50 μm. UV absorbance was measured at 234 nm
using a photodiode array detector equipped with the high performance liquid
chromatography system (HPLC). The results were calculated based on the readings from
a standard series of ATBC.
4.2.4. In vivo studies
4.2.4.1.

Immunization of animals

For all the immunization experiments, Lyophilized OVA protein was dissolved in
PBS buffer or was suspended in different AdjuGel systems with organic solvent ethyl
acetate immediately before injection to obtain a concentration of 1mg/ml. All mice were
given single S.C. inoculation in neck site at day 0. Experimental assignment was shown
in Table 4-1.
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Table 4-1.

Mouse experimental group assignment.

Group Treatment
1
2

Number of
mouse
5
5

Description

Control
S.C. injection with PBS buffer and OVA
AdjuGel 1 +
S.C. injection with AdjuGel 1 and OVA
OVA
3
AdjuGel 2
5
S.C. injection with AdjuGel 2 and OVA
+OVA
4
AdjuGel 3
5
S.C. injection with AdjuGel 3 and OVA
+OVA
Ovalbumin is 50ug per injection. The volume is 50ul per injection.
AdjuGel 1: ethyl acetate (65%, w/w), ATBC (15%, w/w) and PLGA (50:50; IV: 0.65).
AdjuGel 2: ethyl acetate (65%, w/w), ATBC (15%, w/w) and PLGA (85:15; IV: 0.65).
AdjuGel 3: ethyl acetate (65%, w/w), ATBC (15%, w/w) and poly (DL-lactide) (IV:
0.65).
The PLGA concentration in AdjuGel 1, AdjuGel 2 and AdjuGel 3 is 20% (w/w).
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4.2.4.2.

Procedures

All groups were inoculated S. C. once at day 0 and blood samples were collected
every 2 weeks in the first 12 weeks and every 3 or 4 weeks thereafter. Blood samples
were serially diluted with 0.05% Tween 20 in PBS: 1:100, 1:1,000, 1:10,000 and
1:100,000. IgG titers were checked by ELISA (Enzyme-Linked Immunosorbant Assay);
use Log10EC50 as a measure of immune response. EC50 means half maximal effective
concentration and the absorbance of 1:100 dilution was used as the maximum.
4.2.5. Enzyme linked immunosorbent assay (ELISA)
96-well microtiter plates (high protein binding plates from Costar) were coated
overnight with 100 μl coating solution containing 3 μg/mL ovalbumin (OVA) at 4 ϶C. To
remove unbound OVA, plates were washed three times with PBS (pH 7.4) containing
0.05% Tween 20 (PBST). Serum samples (100 μL/ well) from individual mice were
serially diluted in PBST: 1:100, 1:1,000, 1:10,000 and 1:100,000. The plates were then
incubated for two hours at room temperature. The plates were again washed three times
with PBST followed by addition of 100 μL of PBST containing Horseradish Peroxidase
(HRP) -conjugated Goat Anti-Mouse IgG (diluted 1:4000) (Abcam, ab6789). After a two
hour incubation period at room temperature, the plates were washed three times with
PBST followed by the addition of 200 μL of 0.4 mg/ml OPD Peroxidase Substrate
(Sigma P9187, Sigma-Aldrich, St. Louis, MO) and allowed to react for 30 minutes at
room temperature. The optical density (OD) of the reaction was measured at 450 nm
using a Plate Reader. Software BioDataFit was applied to deal with the data by the fourparameter model. Serum titers are reported with Log10EC50.
4.2.6. Statistical analysis
Results are expressed as mean ± S.D. Statistical analysis was carried out for
analyses of differences between means of serum antibody titers using Student’s twotailed t-test. Differences in means were accepted as significant if P was less than 0.05.
4.3.

Results

4.3.1. In vitro release- Ovalbumin
The study of OVA In vitro release showed that the two AdjuGel groups could
provide continuous sustained release of OVA (Table 4-2 and Figure 4-3). In the groups
of PLGA (50:50, IV: 0.65), OVA could be released up to eight weeks; in the groups of
PLGA (85:15, IV: 0.65), OVA could be released up to fourteen weeks. The relatively
hydrophobic PLGA polymer (85:15) could decrease initial release rate of OVA and
prolong the whole release period of OVA. The relatively hydrophobic PLGA polymer
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Table 4-2.

Data of in vitro OVA accumulative release with two groups.

Time
G1(PLGA (50:50)
G2(PLGA(85:15)
Day 0
0±0
0±0
Day 1
0.06±0.004
0.02±0.007
Day 4
0.1±0.008
0.06±0.006
Week 1
0.13±0.007
0.08±0.016
Week 2
0.19±0.009
0.11±0.007
Week 3
0.26±0.009
0.14±0.012
Week 4
0.32±0.008
0.18±0.025
Week 5
0.48±0.023
0.22±0.023
Week 6
0.71±0.053
0.3±0.036
Week 7
0.87±0.027
0.38±0.026
Week 8
1±0.039
0.5±0.018
Week 9
0.63±0.021
Week 10
0.75±0.016
Week 11
0.82±0.002
Week 12
0.91±0.012
Week 13
0.99±0.046
Week 14
1±0.007
G1: 65% ethyl acetate (solvent), 20% PLGA (50:50, IV: 0.65), 15% ATBC and 1mg/ml
lyophilized ovalbumin; G2: 65% ethyl acetate (solvent), 20% PLGA (85:15, IV: 0.65),
15% ATBC and 1mg/ml lyophilized ovalbumin. All ratios are weight to weight. (Mean ±
S. D.)
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Figure 4-3. In vitro OVA accumulative release study with two groups.
Group 1: 65% ethyl acetate (solvent), 20% PLGA (50:50, IV: 0.65), 15% ATBC and
1mg/ml lyophilized ovalbumin; group two: 65% ethyl acetate (solvent), 20% PLGA
(85:15, IV: 0.65), 15% ATBC and 1mg/ml lyophilized ovalbumin. All ratios are weight
to weight.
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increased hydrophobicity of the AdjuGel system, which in turn decreases PBS buffer
penetration into the gel and lower the OVA release rate.
There are no burst releases in the two groups. On day 4, only 10% of total
ovalbumin was released in formulation one. In previous study, 24% of total ovalbumin
was released on day 3 with simailar formulation but using NMP as solvent. Also on day
4, only 6% of total ovalbumin was released in formulation two. But in previous study,
14% of total ovalbumin was released on day 3 with simailar formulation but using NMP
as solvent.
4.3.2. In vitro release- ATBC
The study of ATBC in vitro release showed that the both two groups could
provide delayed release of ATBC (Table 4-3 and Figure 4-4). In the group of PLGA
(50:50), ATBC wouldn’t be released significantly until the sixth weeks; in the groups of
PLGA (85:15), ATBC wouldn’t be released significantly until the thirteenth weeks.
4.3.3. In vivo study
After S.C. injection at the neck sites, no skin lesions were found in all mice. But
two mice showed hair loss in injection sites in group 2 (group AdjuGel 1). It’s not clear
what caused the hair loss, but the fast release of ethyl acetate by group AdjuGel 1 that
contained relatively hydrophilic PLGA (50:50) may probably be related to the issue. The
hair loss was completely recovered within three weeks without treatment.
Three different AdjuGel groups were tested and the results were shown in Table
4-4 and Figure 4-5. They have similar formulation, 65% ethyl acetate (solvent), 20%
polymer, 15% ATBC and 1mg/ml lyophilized ovalbumin. The only difference is the type
of polymer.
In group of AdjuGel 1, relatively hydrophilic polymer PLGA (50:50) was used,
which degraded fast and stimulated an immune response immediately. Statistical analysis
showed the antibody titers of AdjuGel 1 are significant higher than the antibody titers of
control group 1 at time points from week 2 to week 22 (P < 0.01).
In group of AdjuGel 2, relatively hydrophobic polymer PLGA (85:15) was used,
which degraded slowly and stimulated a delayed immune response at week 8. Statistical
analysis showed the antibody titers of AdjuGel 2 have no significant difference compared
with the antibody titers of control group 1 at time points from day 0 to week 6 (P > 0.05).
Until week 8, the group of AdjuGel 2 stimulated a strong immune response. Statistical
analysis showed the antibody titers of AdjuGel 2 are significant higher than the antibody
titers of control group 1 at time points from week 8 to week 22 (P < 0.01).

65

Table 4-3.

Data of in vitro ATBC accumulative release with two groups.

Time
G1(PLGA (50:50)
G2(PLGA(85:15)
Day 0
0±0
0±0
Day 1
0.0128±0.0145
0.0005±0.0006
Day 4
0.0131±0.0001
0.0016±0.0005
Week 1
0.0137±0.0002
0.0018±0.000035
Week 2
0.0149±0.0011
0.0019±0.00003
Week 3
0.0151±0.0002
0.0021±0.00002
Week 4
0.0164±0.0002
0.0023±0.0001
Week 5
0.0167±0.00026
0.0025±0.0001
Week 6
0.0925±0.0587
0.0027±0.00008
Week 7
0.5774±0.164
0.0029±0.00009
Week 8
1±0.07
0.0031±0.0001
Week 9
0.0032±0.00005
Week 10
0.0034±0.00001
Week 11
0.0036±0.00005
Week 12
0.0039±0.0002
Week 13
0.2582±0.145
Week 14
1±0.169
G1: 65% ethyl acetate (solvent), 20% PLGA (50:50, IV: 0.65), 15% ATBC and 1mg/ml
lyophilized ovalbumin; G2: 65% ethyl acetate (solvent), 20% PLGA (85:15, IV: 0.65),
15% ATBC and 1mg/ml lyophilized ovalbumin. All ratios are weight to weight. (Mean ±
S. D.)
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Figure 4-4. In vitro ATBC accumulative release study with two groups.
Group 1: 65% ethyl acetate (solvent), 20% PLGA (50:50, IV: 0.65), 15% ATBC and
1mg/ml lyophilized ovalbumin; group two: 65% ethyl acetate (solvent), 20% PLGA
(85:15, IV: 0.65), 15% ATBC and 1mg/ml lyophilized ovalbumin. All ratios are weight
to weight.
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Table 4-4.
The results of serum anti-OVA IgG antibody titers for group 1, 2, 3
and 4 at different time points of day 0, week 2, 4, 6, 8, 10, 12, 15, 18 and 22.
Time
G1
G2
G3
G4
Day 0
0±0
0±0
0±0
0±0
2 weeks
0.14±0.01
0.96±0.21
0.19±0.05
0.25±0.05
4 weeks
0.11±0.01
1.82±0.1
0.31±0.14
0.66±0.22
6 weeks
0.16±0.04
1.69±0.17
0.63±0.51
0.17±0.64
8 weeks
0.13±0.01
2.13±0.1
1.79±0.42
0.8±0.37
10 weeks
0.15±0.04
2.41±0.15
1.24±0.41
0.7±0.34
12 weeks
0.2±0.02
2.3±0.11
1.44±0.63
1.9±0.1
15 weeks
0.23±0.03
1.46±0.26
1.01±0.45
1±0.06
18 weeks
0.21±0.08
1.88±0.19
1.33±0.5
1.51±0.27
22 weeks
0.15±0.03
1.4±0.13
1.15±0.22
1.35±0.23
P value
0.005*
0.001**
0.001***
Serum anti-OVA total IgG titers were reported with Log10EC50 and results were
expressed as Mean ± S.D.
P values (*G2 vs. G1 with 2 weeks results; ** G3 vs. G1 with 8 weeks results; *** G4
vs. G1 with 12 weeks results)
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Figure 4-5. Mice serum anti-OVA IgG antibody titers.
Group 1, S.C. injection with PBS buffer and OVA; Group 2, S.C. injection with AdjuGel
system containing ethyl acetate (65%, w/w), ATBC (15%, w/w), PLGA (50:50; IV:
0.65)(20%, w/w) and OVA; Group 3, S.C. injection with AdjuGel system containing
ethyl acetate (65%, w/w), ATBC (15%, w/w), PLGA (85:15; IV: 0.65)(20%, w/w) and
OVA; Group 4, S.C. injection with AdjuGel system containing ethyl acetate (65%, w/w),
ATBC (15%, w/w), poly DL-lactide (IV: 0.65)(20%, w/w) and OVA.
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In group of AdjuGel 3, the most hydrophobic polymer poly DL-lactide was used,
which degraded very slow and the approximately degradation time in vivo is 12 – 16
months. As a result, AdjuGel 3 group stimulated a delayed immune response at week 12.
Statistical analysis showed the antibody titers of AdjuGel 3 have no significant difference
compared with the antibody titers of control group 1 at time points from day 0 to week 6
(P > 0.05). At week 8 and 10, although there is significant difference between the
antibody titers of AdjuGel 3 and the antibody titers of control group 1, the values of the
antibody titers of AdjuGel 3 are lower than 1 (0.7 and 0.8). Until week 12, the group of
AdjuGel 3 stimulated a strong immune response. Statistical analysis showed the antibody
titers of AdjuGel 3 are significant higher than the antibody titers of control group 1 at
time points from week 12 to week 22 (P < 0.01).

4.4.

Discussion

New vaccine adjuvants or delivery systems for single dose vaccines have been
studied for a long time. Although controlled release is believed critical for single dose
vaccines, the correlation between patterns of controlled release and immune response was
not clear. Strategy like PLGA microencapsulated antigen proteins was used for delayed
release of antigens. Sanchez et al. reported PLGA microencapsulated Tetanus toxoid
(TT) was programmed to release at two different time points (3 and 7 weeks) in vitro.[47]
However, no successful in vivo data was published for the delayed immune response,
which is probably because the delayed release of antigen proteins is not good enough for
stimulation of an adaptive immune response in vivo.
Here we used a different strategy to achieve the goal of delayed immune response.
We did not only focus on the controlled release of antigen, but also on the degradation
and interaction of polymer and surfactant to delay the onset of adjuvanticity in AdjuGel
system. First, combination of hydrophobic polymer PLGA and plasticizer ATBC
(AdjuGel system) was found capable to induce strong immune response. After several
studies on functions of the individual component (solvent, polymer and plasticizer), it’s
clear that only the combination of hydrophobic polymer PLGA and plasticizer ATBC
could show effective adjuvanticity, any individual component cannot induce effective
response. The combination of hydrophobic polymer PLGA and plasticizer ATBC is
similar to the classic oil based vaccine adjuvants, which require the combination of
surfactants and oil. By comparing the two types of vaccine adjuvants and their modes of
action, we hypothesize the degradation of polymer may be a critical prerequisite for the
adjuvanticity of AdjuGel system.
Then we performed an unsuccessful animal experiment that did not show any
delayed immune response. From the failed experiment, we learned that not only polymer
PLGA and ATBC, but solvent also determined the polymer degradation rate in vivo.
Organic solvent NMP may accelerate the degradation of polymer PLGA by two
possibilities: one is the irritation of NMP causes the local inflammation, which in turn
stimulates innate immunity; another one is the hydrophilicity of NMP enhances the
penetration of non-solvent (water), which also accelerates the PLGA degradation.
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Later, after scrutinizing and evaluating the available organic solvents, we chose ethyl
acetate to replace NMP. Organic solvent ethyl acetate is much less irritating and more
hydrophobic than NMP. Finally, the new formulation showed adjustable delayed immune
responses, which is compatible with the degradation rates of various polymers. These
results proved that our new strategy worked very well for development of new vaccine
formulation with adjustable delayed immune response.
There are other advantages for the new vaccine formulation. In the new
formulation, we used lyophilized antigen proteins. The lyophilized proteins are very
stable in the gel solution of ethyl acetate, PLGA and ATBC because they cannot dissolve
in the gel solution and are kept in solid state. At the same time, the gel solution prevents
the protein from contact with aqueous surrounding. So the new vaccine formulation may
be used for the preparation of vaccines that do not need refrigeration. Thermostable
vaccines will dramatically reduce the cost of cold chain, which consumes about 80% of
the total cost of vaccination programs.[57]
Another advantage is the new vaccine formulation can hold multiple vaccine
antigens. Antigen proteins are suspended in the AdjuGel system, but not conjugated or
attached to polymer. So the solid particles of antigen proteins will be separated and will
not affect each other. By this way, the AdjuGel system may help to prepare polyvalent
vaccine like MMR vaccine, which immunizes against three viruses—the viruses that
cause measles, mumps, and rubella. Polyvalent vaccines can save cost for prophylactic
vaccines. Also polyvalent vaccines may be more effective for therapeutic vaccines like
contraceptive vaccine and cancer vaccine.
4.5.

Conclusion

Our data above indicated that: 1. Organic solvent ethyl acetate was much less
toxic to mice after subcutaneous injection compared with NMP. 2. AdjuGel 1 group,
composed of ethyl acetate, ATBC and PLGA (50:50, IV: 0.65) stimulated a fast immune
response after a single subcutaneous injection. 3. AdjuGel 2 group, composed of ethyl
acetate, ATBC and PLGA (85:15, IV: 0.65) stimulated a delayed immune response on
week 8 after a single subcutaneous injection. 4. AdjuGel 3 group, composed of ethyl
acetate, ATBC and poly DL-lactide (IV: 0.65) stimulated a delayed immune response on
week 12 after a single subcutaneous injection. 5. The delayed period for immune
response was adjustable, which was determined by the degradation rates of polymers.
The lower the polymer degradation rate, the longer the delayed period for immune
response.
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CHAPTER 5.

DEVELOPMENT OF SINGLE DOSE VACCINE WITH THE
ADJUGEL SYSTEM
5.1.

Introduction

After preparation of the new vaccine formulations with adjustable delayed
immune response from the prior section, a single dose vaccine could be developed by two
simultaneous separate inoculations. One used the formulation of group AdjuGel 1 (see
last mouse experiment), which can provide prime or immediate response; another one
used formulation of group AdjuGel 2 (see last mouse experiment), which will provide a
booster or delayed response. We assumed two simultaneous separate inoculations may
mimic two sequential shots that render clear prime response and booster response
5.2.

Experimental Procedures

5.2.1. Materials
Twenty ICR female mice (6-8 weeks) were ordered from Harlan Laboratories.
The biodegradable polymer PLGA were ordered from Lactel Absorbable Polymers,
Durect Corporation, Pelham, AL, USA. Ethyl acetate was ordered from Fisher Scientific;
Acetyl Tributyl Citrate (ATBC) was obtained from Morflex Inc, Greensboro, NC, USA;
Lyophilized Ovalbumin (OVA) as the antigen was purchased from Sigma.
5.2.2. Immunization of animals
For all the immunization experiments, Lyophilized OVA protein was suspended
in different AdjuGel systems with organic solvent ethyl acetate immediately before
injection to obtain a concentration of 1mg/ml. The mice of group 4 were given two
simultaneous separate inoculations: inoculation one used formulation of group AdjuGel 1
(see last mouse experiment) and was injected subcutaneously at the neck site with 50ug
OVA per injection of 50ul; inoculation two used formulation of group AdjuGel 2 (see last
mouse experiment) and was injected subcutaneously at the site of lower back with 50ug
OVA per injection of 50ul. All other mice were given single S.C. inoculation at the site
of neck area with 50ug OVA per injection of 50ul. Experimental assignment was shown
in Table 5-1.
5.2.3. Procedures
All groups were inoculated S. C. once at day 0, and blood samples were collected
every 2 weeks in the first 12 weeks and every 3 or 4 weeks thereafter and serially diluted
with 0.05% Tween 20 in PBS: 1:100, 1:1,000, 1:10,000 and 1:100,000. IgG titers were
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Table 5-1.

Experimental group assignment with two-injections.

Group Treatment
1
2
3
4

Number
of mouse
5
5
5
5

Description

Control
S.C. injection with PBS buffer and OVA
AdjuGel 1 + OVA
S.C. injection with AdjuGel 1 and OVA
AdjuGel 2 +OVA
S.C. injection with AdjuGel 2 and OVA
(AdjuGel 1 +OVA)
S.C. injection with (AdjuGel 1 +OVA) Plus
Plus (AdjuGel 2
(AdjuGel 2 +OVA)
+OVA)
Ovalbumin is 50ug per injection. The volume is 50ul per injection.
AdjuGel 1: ethyl acetate (65%, w/w), ATBC (15%, w/w) and PLGA (50:50; IV: 0.65).
AdjuGel 2: ethyl acetate (65%, w/w), ATBC (15%, w/w) and PLGA (85:15; IV: 0.65).
The PLGA concentration in AdjuGel 1 and AdjuGel 2 is 20% (w/w).
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checked by ELISA (Enzyme-Linked Immunosorbant Assay); use Log10EC50 as a
measure of immune response. EC50 means half maximal effective concentration and the
absorbance of 1:100 dilution was used as the maximum.
5.2.4. Enzyme linked immunosorbent assay (ELISA)
96-well microtiter plates (high protein binding plates from Costar) were coated
overnight with 100 μl coating solution containing 3 μg/mL ovalbumin (OVA) at 4 ϶C. To
remove unbound OVA, plates were washed three times with PBS (pH 7.4) containing
0.05% Tween 20 (PBST). Serum samples (100 μL/ well) from individual mice were
serially diluted in PBST: 1:100, 1:1,000, 1:10,000 and 1:100,000. The plates were then
incubated for two hours at room temperature. The plates were again washed three times
with PBST followed by addition of 100 μL of PBST containing Horseradish Peroxidase
(HRP) -conjugated Goat Anti-Mouse IgG (diluted 1:4000) (Abcam, ab6789). After a two
hour incubation period at room temperature, the plates were washed three times with
PBST followed by the addition of 200 μL of 0.4 mg/ml OPD Peroxidase Substrate
(Sigma P9187, Sigma-Aldrich, St. Louis, MO) and allowed to react for 30 minutes at
room temperature. The optical density (OD) of the reaction was measured at 450 nm
using a Plate Reader. Software BioDataFit was applied to deal with the data by the fourparameter model. Serum titers are reported with Log10EC50.
5.2.5. Statistical analysis
Results are expressed as mean ± S.D. Statistical analysis was carried out for
analyses of differences between means of serum antibody titers using Student’s twotailed t-test. Differences in means were accepted as significant if P was less than 0.05.
5.3.

Results

After S.C. injection, some mice in group 4 showed mild to moderate skin lesions
(local inflammatory reaction at the injection sites). The reason is not very clear. It may
be related to over dose of ethyl acetate or the joint effects of two simultaneous separate
inoculations. The skin lesions were recovered within three weeks after treatment with
antibiotic ointment.
After two simultaneous inoculations, group 4 showed a fast and strong immune
response and seemed to show a booster response at week 12 (Table 5-2 and Figure 5-1).
However, the level of immune response had no significant difference with the level of
immune response in group 2 (control group) (P > 0.05), which means the booster
response is not confirmed.
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Table 5-2.
The results of serum anti-OVA IgG antibody titers for group 1, 2, 3
and 4 at different time points of day 0, week 2, 4, 6, 8, 10, 12, 15, 18 and 22.
Time
G1
G2
G3
G4
Day 0
0±0
0±0
0±0
0±0
2 weeks
0.14±0.01
0.96±0.21
0.19±0.05
1.07±0.15
4 weeks
0.11±0.01
1.82±0.1
0.31±0.14
2.15±0.53
6 weeks
0.16±0.04
1.69±0.17
0.63±0.51
2.18±0.15
8 weeks
0.13±0.01
2.13±0.1
1.79±0.42
1.94±0.34
10 weeks
0.15±0.04
2.41±0.15
1.24±0.41
1.98±0.18
12 weeks
0.2±0.02
2.3±0.11
1.44±0.63
2.44±0.24
15 weeks
0.23±0.03
1.46±0.26
1.01±0.45
1.68±0.08
18 weeks
0.21±0.08
1.88±0.19
1.33±0.5
22 weeks
0.15±0.03
1.4±0.13
1.15±0.22
P value
(12 weeks)
0.30*
Serum anti-OVA IgG titers were reported with Log10EC50 and results were expressed as
Mean ± S.D.
P value with 12 weeks results (* G4 vs. G2)
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Figure 5-1. Mice serum anti-OVA IgG antibody titers with two-injection group.
Group 1, S.C. injection with PBS buffer and OVA; Group 2, S.C. injection with AdjuGel
system containing ethyl acetate (65%, w/w), ATBC (15%, w/w), PLGA (50:50; IV:
0.65)(20%, w/w) and OVA; Group 3, S.C. injection with AdjuGel system containing
ethyl acetate (65%, w/w), ATBC (15%, w/w), PLGA (85:15; IV: 0.65)(20%, w/w) and
OVA; Group 4, S.C. injection with Group 2 and Group 3 simultaneously, one at the site
of neck area and another one at the site of lower back.
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5.4.

Discussion

This experiment didn’t clearly demonstrate two peaks with respective prime and
booster response. There are several possibilities to explain the phenomenon. Firstly, the
two simultaneous inoculations may affect each other and the immediate response may
have inhibited the booster response. Secondly, the prime stimulation may be too strong,
which may have covered the booster response from the formulation of AdjuGel 2.
Further study is needed for optimization of the formulations by designing the onset of
delayed immune response and to find the best combination of different AdjuGel
formulations. Also other immunopotentiators could be added to AdjuGel for better
outcome.
5.5.

Conclusion

Two simultaneous inoculations induced a fast and strong immune response at
week 4 but an equivocal booster response at week 12. Further optimization of AdjuGel
formulations is needed for development of single dose vaccine.
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CHAPTER 6.

RESEARCH SUMMARY

A novel vaccine adjuvant or vaccine delivery system, named AdjuGel system, has
been developed for single dose vaccines with the characteristics of adjustable delayed
immune response.
Formulations for single dose vaccines have be studied for long time. However,
until now no successful formulation or mechanism was developed. We have designed
new vaccine adjuvant formulations by focusing on the booster immune response. Based
on In Situ Implant (ISI) system, the AdjuGel system was designed as a new vaccine
adjuvant formulation, which was composed of organic solvent NMP, hydrophobic
plasticizer ATBC and polymer PLGA. After studies in animal experiments, hydrophobic
plasticizer ATBC and polymer PLGA were confirmed to be the two key components for
effective immune responses in the AdjuGel system.
The oil-based formulations are probably the most classic formulations in vaccine
adjuvants. There are also two key components in oil-based vaccine adjuvant
formulations, hydrophobic oil and surfactant. When compared the adjuGel system to the
oil-based vaccine adjuvant, they displayed similar mode of action: the combination of
two key components is necessary for immunogenicity. Since the hydrophobic plasticizer
ATBC is an oil, we hypothesized polymer PLGA not only acted as a high molecular
weight polymer for sustained release, but also acted as a surfactant in the AdjuGel
system. However, hydrophobic polymer PLGA with high molecular weight will not act
as a surfactant before its degradation. After a period of time for degradation, long
polymer chains will be degraded into shorter ones. As a result, the reduction in molecular
weight produces an increase in hydrophilicity. When the hydrophilicity lipophilicity
balance (HLB) of polymer chains reach a suitable range, hydrophobic polymer PLGA or
PLA will show the characteristics of surfactants, which in turn may alter the AdjuGel
system to be more similar to the classic oil-based vaccine adjuvant and induce immune
response.
Based on the hypothesis above, the AdjuGel system, composed of NMP, ATBC
and PLGA, was tested in an animal experiment. The results didn’t show any delayed
immune response, only showed immediate response with local inflammation at the
injection sites. We realized that probably the irritation and hydrophilicity of NMP caused
the accelerated degradation rate and immediate response.
Since the organic solvent ethyl acetate is less irritating and more hydrophobic
than NMP, it was chosen to replace NMP. The new AdjuGel system is a novel system
composed of ethyl acetate, ATBC and PLGA. It did show modified component release
and adjustable delayed immune responses, which are compatible with the degradation
rates of various polymers. These results confirmed that our new strategy may work for
development of single dose vaccine formulations.

78

LIST OF REFERENCES
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.

Wilson-Welder, J.H., et al., Vaccine adjuvants: current challenges and future
approaches. J Pharm Sci, 2009. 98(4): p. 1278-316.
Plotkin, S.A. and W.A. Orenstein, Vaccines. Fourth ed. 2004, Philadelphia:
Elsevier Inc. 1662.
Freund J, C.J., Hosmer E, Sensitization and antibody formation after injectin of
tubercle bacilli and parafin oil. Proc Soc Exp Biol Med, 1937. 37: p. 509-13
Freund, J., The effect of paraffin oil and mycobacteria on antibody formation and
sensitization; a review. Am J Clin Pathol, 1951. 21(7): p. 645-56.
Herbert, W.J., The mode of action of mineral-oil emulsion adjuvants on antibody
production in mice. Immunology, 1968. 14(3): p. 301-18.
O'Hagan, D.T. and R. Rappuoli, Novel approaches to vaccine delivery. Pharm
Res, 2004. 21(9): p. 1519-30.
Brito, L.A., P. Malyala, and D.T. O'Hagan, Vaccine adjuvant formulations: a
pharmaceutical perspective. Semin Immunol, 2013. 25(2): p. 130-45.
Calabro, S., et al., The adjuvant effect of MF59 is due to the oil-in-water emulsion
formulation, none of the individual components induce a comparable adjuvant
effect. Vaccine, 2013. 31(33): p. 3363-9.
Preis, I. and R.S. Langer, A single-step immunization by sustained antigen
release. J Immunol Methods, 1979. 28(1-2): p. 193-7.
O'Hagan, D.T., et al., Biodegradable microparticles as controlled release antigen
delivery systems. Immunology, 1991. 73(2): p. 239-42.
Alonso, M.J., et al., Biodegradable microspheres as controlled-release tetanus
toxoid delivery systems. Vaccine, 1994. 12(4): p. 299-306.
Langer, R., J.L. Cleland, and J. Hanes, New advances in microsphere-based
single-dose vaccines. Adv Drug Deliv Rev, 1997. 28(1): p. 97-119.
Gupta, R.K., A.C. Chang, and G.R. Siber, Biodegradable polymer microspheres
as vaccine adjuvants and delivery systems. Dev Biol Stand, 1998. 92: p. 63-78.
Jiang, W. and S.P. Schwendeman, Stabilization of a model formalinized protein
antigen encapsulated in poly(lactide-co-glycolide)-based microspheres. J Pharm
Sci, 2001. 90(10): p. 1558-69.
Cui, C., V.C. Stevens, and S.P. Schwendeman, Injectable polymer microspheres
enhance immunogenicity of a contraceptive peptide vaccine. Vaccine, 2007.
25(3): p. 500-9.
Jiang, W., et al., Biodegradable poly(lactic-co-glycolic acid) microparticles for
injectable delivery of vaccine antigens. Adv Drug Deliv Rev, 2005. 57(3): p. 391410.
Oyewumi, M.O., A. Kumar, and Z. Cui, Nano-microparticles as immune
adjuvants: correlating particle sizes and the resultant immune responses. Expert
Rev Vaccines, 2010. 9(9): p. 1095-107.
Conway, M.A., et al., Protection against Bordetella pertussis infection following
parenteral or oral immunization with antigens entrapped in biodegradable
particles: effect of formulation and route of immunization on induction of Th1 and
Th2 cells. Vaccine, 2001. 19(15-16): p. 1940-50.
79

19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.

36.

Leong, K.W., et al., Bioerodible polyanhydrides as drug-carrier matrices. II.
Biocompatibility and chemical reactivity. J Biomed Mater Res, 1986. 20(1): p.
51-64.
Torres, M.P., et al., Amphiphilic polyanhydrides for protein stabilization and
release. Biomaterials, 2007. 28(1): p. 108-16.
Tabata, Y., S. Gutta, and R. Langer, Controlled delivery systems for proteins
using polyanhydride microspheres. Pharm Res, 1993. 10(4): p. 487-96.
Determan, A.S., et al., Protein stability in the presence of polymer degradation
products: consequences for controlled release formulations. Biomaterials, 2006.
27(17): p. 3312-20.
Phanse, Y., et al., Functionalization of polyanhydride microparticles with dimannose influences uptake by and intracellular fate within dendritic cells. Acta
Biomater, 2013. 9(11): p. 8902-9.
Shu, Q., et al., Effects of various adjuvants on efficacy of a vaccine against
Streptococcus bovis and Lactobacillus spp in cattle. Am J Vet Res, 2000. 61(7):
p. 839-43.
Amidi, M., et al., Diphtheria toxoid-containing microparticulate powder
formulations for pulmonary vaccination: preparation, characterization and
evaluation in guinea pigs. Vaccine, 2007. 25(37-38): p. 6818-29.
Heritage, P.L., et al., Novel polymer-grafted starch microparticles for mucosal
delivery of vaccines. Immunology, 1996. 88(1): p. 162-8.
Suckow, M.A., et al., Oral immunization of rabbits against Pasteurella multocida
with an alginate microsphere delivery system. J Biomater Sci Polym Ed, 1996.
8(2): p. 131-9.
O’Hagan, D.T. and E. De Gregorio, The path to a successful vaccine adjuvant–
‘the long and winding road’. Drug discovery today, 2009. 14(11): p. 541-551.
Arya, S.C., Human immunization in developing countries: practical and
theoretical problems and prospects. Vaccine, 1994. 12(15): p. 1423-35.
http://www.grandchallenges.org/Pages/BrowseByGoal.aspx.
Bowersock, T.L. and S. Martin, Vaccine delivery to animals. Adv Drug Deliv
Rev, 1999. 38(2): p. 167-194.
Men, Y., et al., Induction of a cytotoxic T lymphocyte response by immunization
with a malaria specific CTL peptide entrapped in biodegradable polymer
microspheres. Vaccine, 1997. 15(12-13): p. 1405-12.
Moore, A., et al., Immunization with a soluble recombinant HIV protein
entrapped in biodegradable microparticles induces HIV-specific CD8+ cytotoxic
T lymphocytes and CD4+ Th1 cells. Vaccine, 1995. 13(18): p. 1741-9.
Nixon, D.F., et al., Synthetic peptides entrapped in microparticles can elicit
cytotoxic T cell activity. Vaccine, 1996. 14(16): p. 1523-30.
Gupta, R.K., et al., Chronic local tissue reactions, long-term immunogenicity and
immunologic priming of mice and guinea pigs to tetanus toxoid encapsulated in
biodegradable polymer microspheres composed of poly lactide-co-glycolide
polymers. Vaccine, 1997. 15(16): p. 1716-23.
Dunn, R.L., English J.P., Cowsar, D.R., Vanderbilt,D,P., Biodegradable in situ
forming implants and methods of producing the same. 1990: US.

80

37.
38.
39.
40.
41.
42.
43.
44.
45.
46.
47.
48.
49.
50.
51.
52.
53.
54.
55.

Graham, P.D., K.J. Brodbeck, and A.J. McHugh, Phase inversion dynamics of
PLGA solutions related to drug delivery. J Control Release, 1999. 58(2): p. 23345.
Dunn, R.L., Tipton, A.J., Polymeric compositions useful as controlled release
implants. 1997, Atrix lab, Inc: US.
McHugh, A.J., The role of polymer membrane formation in sustained release
drug delivery systems. J Control Release, 2005. 109(1-3): p. 211-21.
Krebs, M.D., et al., Injectable poly(lactic-co-glycolic) acid scaffolds with in situ
pore formation for tissue engineering. Acta Biomater, 2009. 5(8): p. 2847-59.
Packhaeuser, C.B., et al., In situ forming parenteral drug delivery systems: an
overview. Eur J Pharm Biopharm, 2004. 58(2): p. 445-55.
Men, Y., et al., A single administration of tetanus toxoid in biodegradable
microspheres elicits T cell and antibody responses similar or superior to those
obtained with aluminum hydroxide. Vaccine, 1995. 13(7): p. 683-9.
Tabata, Y. and Y. Ikada, Macrophage phagocytosis of biodegradable
microspheres composed of L-lactic acid/glycolic acid homo- and copolymers. J
Biomed Mater Res, 1988. 22(10): p. 837-58.
Shideler, S.E., et al., Use of porcine zona pellucida (PZP) vaccine as a
contraceptive agent in free-ranging tule elk (Cervus elaphus nannodes). Reprod
Suppl, 2002. 60: p. 169-76.
Kirkpatrick, J.F., et al., Long-term effects of porcine zonae pellucidae
immunocontraception on ovarian function in feral horses (Equus caballus). J
Reprod Fertil, 1992. 94(2): p. 437-44.
Vicente, S., et al., A polymer/oil based nanovaccine as a single-dose
immunization approach. PLoS One, 2013. 8(4): p. e62500.
Sanchez, A., et al., Pulsed controlled-released system for potential use in vaccine
delivery. J Pharm Sci, 1996. 85(6): p. 547-52.
Godavarthy, S.S., et al., Design of improved permeation enhancers for
transdermal drug delivery. J Pharm Sci, 2009. 98(11): p. 4085-99.
Lee, P.J., R. Langer, and V.P. Shastri, Role of n-methyl pyrrolidone in the
enhancement of aqueous phase transdermal transport. J Pharm Sci, 2005. 94(4):
p. 912-7.
Kranz, H., et al., Myotoxicity studies of injectable biodegradable in-situ forming
drug delivery systems. Int J Pharm, 2001. 212(1): p. 11-8.
Rungseevijitprapa, W., et al., Myotoxicity studies of O/W-in situ forming
microparticle systems. Eur J Pharm Biopharm, 2008. 69(1): p. 126-33.
Singh, M. and D.T. O'Hagan, Recent advances in veterinary vaccine adjuvants.
Int J Parasitol, 2003. 33(5-6): p. 469-78.
Hong, G., et al., Effect of PMMA polymer on the dynamic viscoelasticity and
plasticizer leachability of PEMA-based tissue conditioners. Dent Mater J, 2010.
29(4): p. 374-80.
Royals, M.A., et al., Biocompatibility of a biodegradable in situ forming implant
system in rhesus monkeys. J Biomed Mater Res, 1999. 45(3): p. 231-9.
ICH Q3C Guideline, Impurities: Residual solvents., in
http://www.emea.europa.eu/pdfs/human/ich/028395en.pdf., FDA, Editor.

81

56.
57.

Grodowska, K. and A. Parczewski, Organic solvents in the pharmaceutical
industry. Acta Pol Pharm, 2010. 67(1): p. 3-12.
Das, P., Revolutionary vaccine technology breaks the cold chain. Lancet Infect
Dis, 2004. 4(12): p. 719.

82

VITA
Qiuye Zhang was born in Nenjiang, China in 1973. After graduating from high
school in 1992, he attended the 7-year program of clinical medicine in Harbin Medical
University, where he received his MD degree in 1999. After graduation, he completed
three years of residency training in the Second Hospital of Harbin Medical University in
2002 and practiced in OB/Gyn in the Second Hospital of Harbin Medical University for
one year. In August 2007, he began his doctoral education in the Pharmaceutical Sciences
Program in the University of Tennessee, Health Science Center, Memphis, from where he
will obtain his PhD in Pharmaceutical Sciences in May 2014.

83

